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 Recent studies have demonstrated that activation of the 5-HT4 receptors in the 
colonic mucosa can have healing and protective actions in experimental models of 
colitis. These actions include increased mucus secretion, increased epithelial 
proliferation, and enhanced epithelial migration. Since these studies involved 
chemically induced models of colitis, the current investigation was conducted to test 
whether a protective action of 5-HT4 receptor stimulation could be detected in 
Interleukin-10 knockout (IL-10 KO), which develop colitis spontaneously due to the 
absence of the anti-inflammatory cytokine, interleukin-10.  
 Upon weaning, the IL-10 knockout mice were separated into two groups: an 
agonist group and a vehicle control group. The agonist group received 1 mg/kg 
tegaserod in a vehicle consisting of 0.9% saline each day by enema of dimethyl 
sulfoxide (DMSO) in saline each day, while the control group received daily enemas 
of vehicle over the course of 21 days. Several outcome measures were used to assess 
the effectiveness of the treatment. To evaluate the severity of colitis, disease activity 
index was monitored, and histologic damage was blindly scored.  
 Administration of tegaserod by enema to the IL-10 KO mice had a significant 
protective effect on the treated mice. The disease activity index (DAI) of agonist 
treated mice was significantly better than that of vehicle treated mice over time 
(p<0.001; 2-way ANOVA). Mice treated with vehicle had a more significant decline 
in health over time versus the agonists, with more blood present in feces and a 
looser/diarrhea-like consistency in stool. The histological damage score (HDS) was 
also improved by 5-HT4 agonist treatment (p<0.05, t-test). Sections of vehicle treated 
colons showed significantly greater damage, including epithelial erosions, the 
presence of polymorphonuclear cells, and abnormal crypt architecture (cryptitis), than 
those treated with the 5-HT4 receptor agonist tegaserod. During the 21-day course of 
the current investigation, there was no difference in the survival data between the two 
groups.  
 These data, when taken together, suggest that administration of the 5-HT4 
receptor agonist tegaserod via enema to IL-10 KO mice has a greater healing and 
protective effect than seen in the IL-10 KO mice that received vehicle. We proposed 
to test the hypothesis that treatment of IL-10 knockout colitis with a 5-HT4 receptor 
agonist will attenuate the development of colitis and have healing and protective 
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
The Gastrointestinal Tract:  
 The gastrointestinal (GI) tract is an important organ system that extends from 
the mouth to the anus. It includes the esophagus, stomach, the large intestine, and the 
small intestine. Within the small intestine, there is also the duodenum, jejunum, and 
ileum. The GI tract is also associated with other organs such as the liver, pancreas and 
gall bladder. In addition, sphincters, such as the lower esophageal sphincter, play 
important physiologic roles, such as the regulation of passage of gut contents between 
areas of the GI tract. Next, the wall of the GI tract is organized into three layers, with 
each layer composed of different cell types. While the arrangement of the layers of 
the gut wall and the cellular components is similar along the length of the gut, there 
are differences. An example is the arrangement of the epithelium and smooth muscle 
thickness in different regions of the gut. Many of the gut’s functions, like digestion, 
absorption of nutrients, movement, and defecation, occur due to coordinated actions 
of gut cells like smooth muscle cells, intrinsic neurons and different kinds of epithelial 
cells. These epithelial cells include absorptive enterocytes, mucus secreting goblet 
cells, and enteroendocrine cells (Saffrey 2014).  
 Next, the communication between the GI tract and brain by way of extrinsic 
autonomic and sensory nerves, as well as the hormones that are produced by 
endocrine and enteroendocrine cells is important. This communication occurs through 
the gut-brain axis and is bidirectional. While extrinsic signals regulate gut functions, 
information relayed from the gut by enteric neurons, extrinsic sensory neurons, and 
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enteroendocrine cells has influence over some central nervous system (CNS) activities 
which has impacts on behaviors, including the regulation of appetite.  
 The primary function of the GI tract is to break down food into nutrients to be 
used to generate energy for survival and reproduction (Sharkey and Savidge 2014). A 
secondary function is the defense of the host from ingested harmful food antigens, as 
well as bacteria, parasites, and toxins (Sharkey and Savidge 2014). The defensive 
function of the GI tract aids in the protection of not only the organ, but the host, from 
harmful effects of digestion, such as extreme pH, digestive enzymes, bile, and other 
potentially damaging chemicals (Fasano and Shea-Donohue 2005, McCole and 
Barrett 2007, Turner 2009). Digestion commonly produces antigenic peptides that can 
be dangerous to the host and lead to intense immune responses if not carefully 
regulated.  
 Important components of the GI tract are the small and large intestines, as 
disorders of the intestines is prevalent, mostly in the form of Inflammatory Bowel 
Disease (IBD) and Irritable Bowel Syndrome (IBS). IBD is a chronic inflammatory 
condition that causes many issues, like potential for obstruction, formation of ulcers, 
and damage to the epithelium. These issues can be best visualized histologically.  
 The small intestine, which measures about 20 feet in length, is the longest 
portion of the GI tract, and it serves as the primary site of digestion and absorbtion. 
The small intestine is divided into three segments, the first, the duodenum starts at the 
pyloris of the stomach, and is connected to the posterior abdominal wall, this is where 
absorption begins the jejunum is the next segment and is connected to the distal end 
of the duodenum. The jejunum is suspended from the posterior wall on the mesentery 
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and is where products of digestion are absorbed into the blood stream. Following this 
is the ileum, which makes up a large portion of the small intestine (three-fifths) and is 
also supported by mesentery. The ileum absorbs any remaining nutrients not absorbed 
by the jejunum, as well as bile acids. The small intestine is segmented in three parts 
because this allows for better breakdown and absorption of food and nutrients. The 
small intestine is organized primarily for the absorption of nutrients from food. Its 
efficacy in this matter is enhanced by many structural devices that increase the surface 
area. One such structural device is the length of the small intestine, at over 4 meters in 
length it is the longest portion of the GI tract. The surface area of the small intestine is 
further increased by transverse folds of the mucosa and submucosa called the plicae 
circulares, which project into the lumen. The plicae circulares are 8-10 mm in height, 
3-4 mm thick, and are visible to the naked eye. The plicae circulares are enduring 
structures of the small intestine and are not flattened out by the distention of the 
intestine. They are most noticeable first in the first part of the jejunum, after which 
they diminish in number and height, and are not found in the ileum. The plicae 
circulares function to slow the passage of material through the intestine, and likely 
increase the surface area 3-fold. Small intestinal surface area is also increased by the 
intestinal villi. They are 0.1-0.5 mm in length, and are thin, leaf-like structures which 
project into the lumen. The intestinal villi are longest in the duodenum and proximal 
jejunum and decrease in length and become more cylindrical in the distal end of the 
jejunum and ileum. Villi are not present in the large intestine.  
 The large intestine, also called the colon, is shorter than the small intestine, 
measuring about the length of one’s height. It is the primary site affected by the 
chronic inflammation that IBD is characterized by. There are seven regions within the 
4 
 
large intestine, in order as follows: the cecum, ascending colon, transverse colon, 
descending colon, sigmoid colon, rectum and anus. The function of the colon is to 
concentrate indigestible residues left over from food by absorbing water and 
electrolytes, and then moving these residues to the rectum to be eliminated. The 
mucosal surface is relatively smooth, containing no folds or villi. The surface 
epithelium, and the upper third of the glands, contains columnar absorptive cells and 
goblet cells. The lower two-thirds contain mostly goblet cells, and a small number of 
enteroendocrine cells and stem cells. The goblet cells are responsible for the secretion 
of mucus to coat the surface of the epithelium.  This provides a protective, physical 
barrier between the epithelial surface and the microbes within the lumen of the colon, 
aids in the movement of content through the bowel. This secreted mucus also serves 
to protect the surface from damage that could be caused by increasingly concentrated 
contents. The lifespan of most epithelial cells is around 7 days. The stem cells divide 
often to generate new cells, which then move to a maturation area. At the maturation 
area the stem cells undergo structural and enzymatic maturation, and then provide the 
functional cell population of each region of the colon. The cells at the end of their 
lifespan are then shed in an area called the extrusion zone. 
 The layers of the colon wall include the mucosa, the submucosa, and the 
muscularis externa. Within these layers lie important histologic features of the colon 
that are affected by the characteristic chronic inflammation found in IBD. In the 
mucosa are crypts, which are test-tube like structures attached to the muscularis 
mucosae, a thin smooth muscle layer at the base of the mucosal layer. The crypts are 
covered by the colonic epithelium and contain a myriad of cell types like 
enteroendocrine cells, goblet cells, and enterocytes.  
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Histologic Features of Colonic Inflammation 
 Chronic inflammation, which is common in IBD, can damage many of these 
structures. In IBD, common histological changes include a disruption of the 
epithelium, an alteration in crypt architecture, such as branching crypts (cryptitis), the 
formation of abscesses, erosions, and ulcers. In addition, chronic inflammation can 
cause the infiltration of polymorphonuclear cells and mononuclear cells. One of the 
goals in the treatment of IBD is histological healing, or in other words, a return to a 
“healthy” appearance, as assessed by examination of histological sections of biopsy 
specimens (Marchal Bressenot, Riddell et al. 2015). In UC, this is the ultimate end 
goal, whereas in CD it is a minimum requirement for treatment. However, a generally 
accepted definition of histological healing does not currently exist. Though it should 
be noted that histological assessment, when used in drug trials, focuses primarily on 
improvement of inflammatory features and their regression. Histologic assessment of 
tissues is done with Hematoxylin and Eosin (H&E) stained sections of colon.  
 Examining the pathology of IBD relies mostly on two varieties of lesions 
which are architectural abnormalities, such as crypt branching or shortening, a 
decrease in the density of crypts, and an abnormal mucosal surface, and inflammatory 
features, such as an increase of mononuclear and polymorphonuclear cells in the 
lamina propria, and the presence of granulomas, ulcers and erosions (Jenkins, Balsitis 
et al. 1997, Geboes and Dalle 2002). It is important to note, however, that these 
histological features of IBD are variable over time as a result of the natural evolution 
of the disease, as well as the use of therapeutics. An example of the variable 
histologic features in IBD can be seen in UC, where, in the early stages, crypt 
distortion is not seen. Further, crypt architectural abnormalities can take up to 2 
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months to arise (Schumacher, Kollberg et al. 1994, Theodossi, Spiegelhalter et al. 
1994). In addition, the decrease in the density of the crypts is generally not seen in the 
first week of UC and is present in nearly 75% of patients with UC in remission 
(Rubio, Johansson et al. 1982). Also, some histological features can help distinguish 
IBD patients from healthy subjects in nearly 90% of cases (Jenkins, Goodall et al. 
1988). 
 In the realm of inflammatory features, increases in the cellularity of the lamina 
propria aids in discerning IBD afflicted patients from healthy subjects. Another 
histological feature used in this regard is an increase in plasma cells, where it was 
shown that there is an increase in IBD rectal samples as compared to controls (Scott, 
Goodall et al. 1983). While histological findings can aid in the identification of IBD, 
it should always be kept in mind that inflammatory features of IBD are not constant 
over time. This is evident in that granulomas, which are a distinct feature of CD, are 
not constantly present. They are generally seen in the early phases of the disease, and 
in children (Geboes and Dalle 2002, Rubio, Orrego et al. 2007).  
 In terms of disease activity, histological assessment is generally based on the 
combination of the presence of neutrophils and epithelial damage (Villanacci, 
Antonelli et al. 2013). Neutrophils can be recognized reliably, and they are known to 
release molecules that can damage tissue. It should be noted that the activity status of 
macrophages and lymphocytes cannot be assessed by H&E stained sections, and the 
influence of eosinophils remains unclear. However, elevated levels of eosinophils 
have been observed in colonic biopsy samples from patients with UC, and it has been 
noted that increased numbers of these eosinophils, as well as eosinophil-derived 
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granular proteins, correlate with morphological changes in the GI tract, disease 
severity, and GI dysfunction (Saitoh, Kojima et al. 1999, Carvalho, Elia et al. 2003).  
 Histologic assessment of mucosal healing is important. It is characterized by 
the resolution of abnormalities in crypt architecture and infiltration of inflammatory 
cells. Structurally, mucosal healing is associated with intact barrier function of the gut 
epithelium preventing the translocation of commensal bacteria and antigens in the 
lumen into the mucosa (Neurath 2012). The mucosa may, however, still show features 
of sustained damage, such as a decrease in crypt density, with cryptitis present (Price 
and Morson 1975, Rubio, Johansson et al. 1982). Though it should be noted that in 
some patients the mucosa appears to return to normal. Also, with mucosal healing, a 
reduction of epithelial regeneration generally reduces the depletion of mucin 
(Serafini, Kirk et al. 1981). The inflammatory cell infiltrate is variable in composition. 
It can be seen as a hypercellular lamina propria containing acute and chronic 
inflammatory cells, or a hypocellular lamina propria containing a reduction in the 
number of mononuclear cells. In remission, ultimately, the chronic inflammation 
decreases along with the basal plasmacytosis. With the persistence of a high number 
of eosinophils, and cellularity within the lamina propria gives a high risk of relapse 
(Schumacher, Kollberg et al. 1994, Bitton, Peppercorn et al. 2001, Azad, Sood et al. 
2011). In terms of relapse predictions, there are certain histological features that may 
be indicative such as acute inflammatory cell infiltrate, the presence of crypt abscess, 






 Serotonin was first discovered in 1937 by Vittorio Erspamer. He first extracted 
it from rabbit gastric mucosa and called it “enteramine”. Nearly a decade later the 
team of Rapport, Page, and Green reported that they had isolated a compound found 
in bovine serum. They named it “serotonin” after its vasoconstrictive properties. A 
few years after the team of Rapport, Page, and Green reported their discovery, the 
structure was elucidated as the 5-Hydroxytryptamine (5-HT), and it was ultimately 
shown that enteramine and serotonin are one in the same. The name serotonin stuck 
simply because it was made available to researchers by the pharmaceutical company 
Upjohn Pharmaceuticals, referring to the compound as serotonin. In terms of function, 
Erspamer hypothesized that serotonin must be key in the gut, as he found it in the 
gastrointestinal tract of every vertebrate he studied. He also noted that the majority of 
serotonin is synthesized and contained within the gut.  
Serotonin in the gut:  
 With a majority of our serotonin being found in the gut, it is important to 
understand serotonin’s functions there. Serotonin is present in the gut primarily in two 
sources. These are the enterochromaffin cells (EC cells) and myenteric neurons which 
project in descending pathways. The majority of the serotonin is contained in the EC 
cells (Mawe and Hoffman 2013). These two sources of serotonin are differentiated by 
their cellular location as well as their different synthetic pathways. In EC cells, 
located in the intestinal mucosa, serotonin is synthesized from L-tryptophan, and is 
mediated by the rate-limiting enzyme tryptophan hydroxylase 1 (TPH1). In neurons, 
however, serotonin is synthesis is mediated by tryptophan hydroxylase 2 (TPH2). 
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Neurons that contain serotonin, although small in amount (roughly 2% of myenteric 
neurons), have extensive projections, which suggests a role in modulating or initiating 
gut motility. Among these projections, those that could be considered most important 
in terms of gut motility would be those that project to other serotonergic neurons 
which would form a descending network of serotonergic neurons.  
 In terms of signaling, there are no intercellular degradative enzymes that 
degrade serotonin (Mawe and Hoffman 2013). This is because at physiological pH, 
serotonin is highly charged, and as such requires a transport mechanism to cross the 
plasma membrane where it can be degraded by intracellular enzymes like monoamine 
oxidase. In terms of reuptake, the serotonin selective reuptake transporter (SERT) is 
responsible for the reuptake of serotonin in not only the brain but in the 
gastrointestinal tract as well. As such, SERT is expressed by all of the epithelial cells 
in the intestinal mucosa (Mawe and Hoffman 2013). SERT internalizes serotonin 
through a sodium- and chloride-dependent mechanism. Due to the ubiquitous 
expression of SERT by the epithelial cells in the intestinal mucosa, SERT acts to 
remove serotonin from interstitial space, once released by the enterochromaffin cells. 
As such, SERT is critical in the role of local regulation of serotonin availability and 
action within the intestine.  
 Serotonin released from EC cells mediates many gastrointestinal functions 
such as motility, mucus secretion, perception of pain and nausea, and vasodilation 
(Mawe and Hoffman 2013). This is achieved through a diverse family of serotonin 
receptors, located on intrinsic and extrinsic nerve fibers that are located within the 
lamina propria. Serotonin interacts with many receptors that are present in the gut. 
There are 7 subtypes of serotonin, and within each subtype are many variants. Within 
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the 7 subtypes, the 5-HT3 and 5-HT4 families have been studied the most in terms of 
gut motility. In addition to these, the 5-HT7 family have also been hypothesized to 
have some hand in regulating gut motility, but their therapeutic usefulness and 
physiological role have yet to be elucidated. The two serotonin receptor subtypes that 
have been most extensively exploited as therapeutic targets in the gut are the 5-HT3 
and 5-HT4 receptors. 
5-HT3:  
 The 5-Hydroxytryptamine 3 (5-HT3) receptor is one of the subtypes of 
serotonin receptors mentioned above. It is part of the family of cys-loop ligand-gated 
ion channels. It is permeable to sodium, potassium, and calcium, and as such mediates 
rapid depolarizing responses in both pre and post synaptic neurons (Lummis 2012). In 
therapeutic use, 5-HT3 receptor antagonists block afferent and efferent synaptic 
transmission. In terms of a physiological role, the 5-HT3 receptor coordinates emesis 
and regulates motility and secretion within the gastrointestinal tract. As such, in 
therapeutic use the 5-HT3 receptor antagonist is used to combat nausea and vomiting 
common in cancer chemotherapy, radiation, and anesthesia. Also, the 5-HT3 receptor 
antagonist has found success in dealing with diarrhea predominant Irritable Bowel 
Syndrome. In the neurons where 5-HT3 is localized at resting membrane potential, the 
electrochemical gradient favors sodium and potassium. As such, 5-HT3 receptors 
depolarize neurons and mediate fast, excitatory synaptic transmission.  
 A large number of 5-HT3 receptors can be found in the gastrointestinal tract as 
well as the peripheral nervous system (Lummis 2012). The 5-HT3 receptors have 
their best documented effects in the gut, where they are said to regulate 
gastrointestinal motility and the vomiting reflex. They have also been indicated to 
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play a role in visceral pain and inflammation. In terms of the actual receptor, to date, 
5 subunits have been cloned, so called A, B, C, D, and E. However, only the A and B 
subunits have been studied extensively. The 5-HT3 receptor has much in common 
with the cys-loop family to which it belongs: it is an integral membrane protein, 
pentameric in structure, containing a central ion channel pore. Mariq et al suggest the 
structure of the 5-HT3 receptor as a long extracellular N-terminus, four 
transmembrane spanning domains (TM1-TM4), and a short C-terminus. The N-
Terminal domain would contain the recognition site for serotonin, the binding of 
which would occur through the interface of two subunits. With the homomeric A 
subunit of 5-HT3, there are five possible binding sites. However, only binding two 
molecules of agonist are necessary to open the channel and are sufficient to do so. 
Within these subunits are amino acid domains, “loops”, which participate in binding.  
 The 5-HT3 receptor has been studied in various animals (mouse, human, dog) 
and it has been noted that the receptors, in the animals studied, have similar ion 
permeabilities and current-voltage relationships (Machu 2011). Although the receptor 
orthologs have similar agonist potencies (including in serotonin) and affinities for 
numerous competitive antagonists, there are some differences in ligand recognition. In 
example, the human 5-HT3A receptor has a much lower affinity (1800 fold) for 
curare, a competitive antagonist of the 5-HT3 receptor than the 5-HT3A receptor 
found in mice (Machu 2011).  
 In terms of binding at the 5-HT3 receptor, when an agonist binds, it causes a 
conformational change in the receptor which results in channel opening. The site 
where the ligand binds is composed of loops from the principal face of one subunit 
and a series of β strands from the complementary face of an adjacent subunit. When 
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an agonist binds to the ligand binding domain, it is thought to initiate movement 
through bringing Loop C of the ligand binding domain from an uncapped and 
disengaged state to a capped and engaged position. Experimental evidence from 
several groups suggests that several “loops” are involved in the binding process. Loop 
2, Loop 7 (the cys-loop), Loop 9 (from the opposing face of the ligand binding 
domain), and Loop 10 interact with transmembrane 2 – transmembrane 3 linker 
regions (Machu 2011). As these “loops” interacting with the transmembrane 2-3 
linker region, they play key roles in transmitting agonist binding to channel opening. 
The transmission of agonist binding to channel opening is achieved by electrostatic 
and/or hydrophobic interactions, such that the movement of the transmembrane 2-3 
linker moves the transmembrane-2, which is the channel lining element, resulting in 
channel opening.  
Therapeutic Use of 5-HT3:  
 5-HT3 receptor antagonists are commonly used to treat various forms of 
nausea and vomiting. Vomiting is coordinated by neurons in the medulla oblongata. It 
is a complex process which requires stepwise gastric fundus relaxation, followed by 
intense contraction of abdominal, intercostal, and diaphragmatic muscles, then closing 
of the glottis, and relaxation of the upper esophageal sphincter prior to the expulsion 
of gastric contents (Machu 2011). The physiological responses leading to vomiting 
are caused by the activation of many efferent neurons, whose nuclei are spread 
through the medulla oblongata. Nausea and vomiting can be initiated by various 
factors. Harmful chemicals and toxins can act directly on the gastric and duodenal 
mucosa to stimulate abdominal vagal afferent nerves. These project to the dorsal 
vagal complex which contains the nucleus of the solitary tract, the dorsal motor 
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nucleus of the vagal nerve, and the area postrema. Circulating harmful chemicals act 
directly at the chemoreceptor trigger zone (CTZ) of the area postrema which is 
located on the floor of the fourth ventricle, an area of the CNS that is not bound by the 
blood-brain-barrier. Motion sickness and other vestibular disturbances stimulate 
nausea and vomiting. Changes in intracranial pressure, brain trauma, or lesions in/near 
the vomiting center can evoke vomiting, in addition, extreme emotion, bad odors, or 
hormonal changes associated with pregnancy can also elicit nausea and/or vomiting. 
Also, gastrointestinal dysfunction, such as gastroparesis, can produce nausea and 
vomiting. 
 In terms of the development of 5-HT3 receptor antagonists and the recognition 
that it plays a role in nausea and vomiting, these actions were discovered before the 5-
HT3 receptor was identified as a ligand gated ion channel (Machu 2011). Two 
laboratories in the 1950’s identified the 5-HT3 receptor through contraction of guinea 
pig ileum. Due to the ability of morphine to block the contractile response seen in this 
newly identified receptor, it was named “5-Hydrpxytryptamine M”. In the mid-late 
1970’s Fozard and colleagues identified this 5-HT-M receptor in rabbit heart and set 
to investigating it. They observed that metoclopramide, a dopamine receptor 
antagonist, blocked the action of serotonin at the 5-HT-M receptor. This led to 
development of 5-HT-M selective agents. In the early 1980’s, Florczyk and 
colleagues showed that a high dose of metoclopramide relieved cisplatin, a cancer 
chemotherapy drug, induced vomiting in ferrets. This then led two groups of 
investigators to show that an early 5-HT-M receptor antagonist, MDL 72222, was 
very effective in eliciting the same effect: reducing cisplatin-induced vomiting. 
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 The mechanism, or mechanisms, by which 5-HT3 receptor activation causes 
nausea and vomiting could involve both a central, and peripheral, component. In the 
gastrointestinal tract, EC cells release serotonin in response to mucosal irritation, or 
cellular damage. The released serotonin binds to 5-HT3 receptors on vagal afferent 
nerves in the duodenal mucosa, which project to the dorsal vagal complex of the 
vomiting center. 5-HT3 receptors are on nerve terminals of the projecting vagal 
afferent nerves to the dorsal vagal complex. Post-synaptic 5-HT3 receptors could also 
be present in the dorsal vagal complex. Aside from the 5-HT3 receptor, there are three 
other classes of major neurotransmitter receptors that have been identified as targets 
for antiemetic drugs. These are the dopamine D2 receptor, the muscarinic M1 
receptor, and the histamine H1 receptor. That there are so many drugs to combat 
nausea and vomiting (5-HT3 receptor antagonists, D2 receptor antagonists, 
antihistamines, and muscarinic M1 antagonists) elucidates that no single class of 
drugs can successfully stop the nausea and vomiting brought about by various causes. 
As such, the 5-HT3 receptor antagonists are primarily used to combat nausea and 
vomiting associated with chemotherapy, radiation treatment, and radiation surgery. 
The 5-HT3 receptor antagonists have little efficacy in treating other causes of emesis. 
5-HT3 and Inflammatory Bowel Disease/Irritable Bowel Syndrome:  
 In addition to treating nausea and vomiting, 5-HT3 receptor antagonists have 
been used to combat diarrhea predominant Irritable Bowel Syndrome (IBS-D). IBS is 
a disorder characterized by periods of intense abdominal symptoms, followed by 
periods of no symptoms. Severe intestinal cramping or pain, in the absence of other 
disease, is the “calling card” of IBS. IBS can be accompanied by diarrhea, 
constipation, or an alternation of both. Over the period of 1 year, a patient must 
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experience at least 12 weeks of abdominal pain or discomfort, accompanied by at 
least 2 of the following 3 features: Abdominal distress relieved by defecation (1), 
abdominal distress accompanies a change in stool frequency (2), or there is an 
associated change in the appearance of the stool (3) (Machu 2011). IBS has sub-types, 
constipation predominant, diarrhea predominant, mixed, alternating, or unspecified, 
which is based upon the consistency of the stool of the patient. IBS is prevalent, with 
an occurrence of 10-20% worldwide.  
 Gastrointestinal function is regulated by intrinsic and extrinsic factors, which 
include endocrine and paracrine mediators (Machu 2011). In addition, the 
gastrointestinal tract is regulated by the sympathetic, parasympathetic, and enteric 
divisions of the autonomic nervous system. In the enteric nervous system, nerve 
plexuses form reflex arcs which coordinate activity within the gastrointestinal tract. 
The enteric nervous system can function independently of the parasympathetic and 
sympathetic nervous systems, however, the enteric nervous system modulated by their 
input. IBS has both altered motility (constipation, diarrhea), and increased visceral 
sensitivity. As there are a large number of hormones and neurotransmitters that are 
involved in gastrointestinal motility, as well as in transmitting sensory information 
within the gut, like pain, it should come as no surprise that there is a myriad of drug 
classes involved in the treatment of IBS, such as 5-HT4 agonists, 5-HT3 antagonists, 
anticholinergics, and probiotics. The underlying mechanisms surrounding IBS are not 
well understood. It is likely that they are multi-faceted, and likely differ based on the 
subtype of IBS a given patient has.  
 One of the roles of 5-HT3 receptors is to transmit sensory information to the 
central nervous system. This sensory information includes pain via spinal afferent 
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nerves, and non-painful sensory information such as the sensation of bloating done 
through parasympathetic afferent nerves (Gershon and Ratcliffe 2004). As such, the 
5-HT3 receptor antagonist alosetron has been marketed as having the capability to 
reduce the visceral sensation that is associated with IBS-D. 
 5-HT4:  
 The 5-hydroxytryptamine 4 (5-HT4) receptor is G-protein coupled and 
promotes activation of the adenylate cyclase/ cyclic adenosine monophosphate 
(cAMP)/protein kinase A pathway (Hoffman, Tyler et al. 2012). It can affect a variety 
of cellular functions that include the facilitation of neurotransmitter release. In 
stimulating the presynaptic 5-HT4 receptors on the myenteric cholinergic nerve 
terminals, there is an enhanced fast excitatory synaptic input to neurons. There is also 
an increase in neurogenic muscle contractions in the intestines. Thus, presynaptic 
facilitation in the peristaltic reflex circuitry is thought to be responsible for the 
prokinetic actions seen in 5-HT4 receptor agonists.   
 In addition to the 5-HT3 receptor, the 5-HT4 receptor has been targeted for 
potential therapeutic effects. Stimulation of presynaptic 5-HT4 receptors through the 
intrinsic reflex circuitry of the gut potentiates the release of acetylcholine, substance 
P, and calcitonin gene related peptide. 5-HT4 receptor agonists, such as tegaserod, 
and cisapride, have been used in constipation predominant IBS (IBS-C), chronic 
idiopathic constipation, functional dyspepsia, and gastroparesis. However, both 
tegaserod and cisapride were pulled from the market for cardiovascular related side 
effects. Cisapride was pulled due to association with cardiac arrhythmias, such as 
ventricular tachycardia, ventricular fibrillation, and Torsades-de-pointes (Wong, 
Manabe et al. 2010). Tegaserod was pulled because of concern due to possible 
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ischemic cardiovascular events, but epidemiological studies performed failed to show 
such a correlation (Anderson, May et al. 2009, Loughlin, Quinn et al. 2010). It should 
be noted, however, that tegaserod and cisapride are not as selective for 5-HT4 
receptors as the newer generation of agonists, such as velusetrag and prucalopride. 
Tegaserod, in addition to being an agonist at the 5-HT4 receptor, also interacts with 
the 5-HT 1B and 1D receptors as an agonist and the 5-HT2B receptor as an 
antagonist. Cisapride inhibits the human ether-àgo- go related gene (hERG) potassium 
channel at therapeutic concentrations (Wong, Manabe et al. 2010, Beattie, Armstrong 
et al. 2011). This inhibition of hERG can lead to QT prolongation and ultimately 
Torsades-de-pointes, as well as ventricular tachycardia, ventricular fibrillation. These 
off-target interactions are likely responsible for the cardiovascular events that resulted 
in the pulling of cisapride from the market and what raised concern about tegaserod.  
 With cisapride and tegaserod having been removed the market, a new 
generation of 5-HT4 receptor agonists was needed to combat IBS-C. Prucalopride is 
one such agent. As a part of the newer generation of 5-HT4 receptor agonists, 
prucalopride has a greater selectivity, and a higher affinity for, the 5-HT4 receptor. It 
promotes cholinergic and non-adrenergic, non-cholinergic neurotransmission via 
enteric neurons (Wong, Manabe et al. 2010). Prucalopride shows high affinity in 
binding to the 5-HT4 isoforms A and B. It also shows more than a 290-fold selectivity 
for the 5-HT4 receptor than other receptors to which it has shown ability to bind 
(namely the dopamine D4 receptor, 5-HT3 receptor, and alpha-1 receptor) (Wong, 
Manabe et al. 2010). As an agonist binding to the 5-HT4 receptor, prucalopride 
activates adenylate cyclase, as well as increasing intracellular cAMP levels. In 
addition, in the 5-HT4 receptors present in the gastrointestinal tract, there is a 
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promotion of increase motility and mucus secretion. As a result, in human studies 
prucalopride has shown an increase in stool frequency, as well as a loosening of stool. 
There was also an accelerated gastric emptying half-time, ascending colon emptying 
half-time, overall colonic transit, and whole gut transit. It should also be noted that, in 
contrast with cisapride and tegaserod, prucalopride has a high selectivity for the 5-
HT4 receptor, which minimizes interactions with other receptors that would lead to 
serious adverse effects. 
 Also, prucalopride induces a smaller increase in the L-type calcium current as 
compared with serotonin  (De Maeyer, Lefebvre et al. 2008). This would mean that it 
would be unlikely that prucalopride could bring forth atrial arrhythmias in patients 
being treated for constipation. It would instead block cardiac 5-HT4 receptors and 
could potentially prevent arrhythmogenic effects of serotonin. In addition, it is 
eliminated from the body without much metabolism, reducing potential drug-drug 
interactions with medications that affect hepatic or renal metabolism and clearance. 
There is also the possibility that 5-HT4 receptor agonists can act through a mucosal 
site of action (Hoffman, Tyler et al. 2012). Luminal administration of 5-HT4 receptor 
agonists promotes propulsive motility, as well as enhancing the ascending contractile 
and descending relaxatory limbs of the peristaltic reflex.  
 The 5-HT4 receptor, in addition to therapeutic use for IBS-C and 
gastroparesis, has been studied in some mouse models of colitis. Spohn and her 
colleagues in the Mawe laboratory showed the efficacy of 5-HT4 receptor agonists in 
two chemically induced models of colitis, namely Dextran sodium sulfate (DSS) and 
2,4,6-Trinitrobenzene sulfonic acid (TNBS). She showed that in these models of 
colitis, the 5-HT4 receptor, when acted upon by an agonist, attenuated the 
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development of colitis, and accelerated healing from already established colitis 
(Spohn, Bianco et al. 2016). The 5-HT4 receptor agonist treatment was given by 
enema, which would limit its adverse effects, but as seen in Dr. Spohn’s paper, did 
not limit its efficacy. Administration of a 5-HT4 agonist systemically by 
intraperitoneal injection failed to affect inflammation, and enema administration of 
the agonist was ineffective in 5-HT4 null mice.  
 Evidence collected to date indicates that the protective action of epithelial 5-
HT4 receptor activation involves protection and restoration of the epithelial barrier.  
Animals given the 5-HT4 receptor agonist by enema showed a significant increase in 
epithelial proliferation, as measured by quantification of Ki67-immunoreactive cells. 
Furthermore, in experiments involving Caco-2 cells, a human colonic 
adenocarcinoma cell line, the 5-HT4 agonist increased the rate of cell migration and 
led to a resistance to oxidative stress-induced apoptosis (Spohn, Bianco et al. 2016).  
Together, along with the knowledge that 5-HT4 agonists activate mucus secretion 
from goblet cells (Hoffman, Tyler et al. 2012), these findings support the concept that 
5-HT4 agonist promote healing by assisting with the restoration of the epithelial 
barrier.   
 In the body, the 5-HT4 receptor is widely expressed. Activation of the 5-HT4 
receptor, in the periphery, has been shown to be involved in several responses in 
various organs like the gastrointestinal tract, the heart, and the urinary bladder (De 
Maeyer, Lefebvre et al. 2008). The 5-HT4 receptor is also present in the brain, where 
its highest expression can be found in the limbic structures, hippocampus, and the 
basal ganglia, which are linked to cognition. Thus the 5-HT4 receptor has been 
20 
 
implicated in various pathological disorders and represents a valuable target for 
designing new drugs.  
 That the 5-HT4 receptor is involved in peristalsis in humans, mice, and many 
other animals is well documented. Mucosal stimulation induces the release of 
serotonin from enterochromaffin cells, which activates intrinsic primary afferent 
neurons (IPANs) (De Maeyer, Lefebvre et al. 2008). This then releases acetylcholine 
(ACh) as well as calcitonin gene related peptide (CGRP). These neurotransmitters 
then connect through interneurons to ascending excitatory or descending inhibitory 
motor neurons, which results in ascending contraction and descending relaxation. 
Through functional studies and radioligand binding in the intestine, it is suggested 
that 5-HT4 receptors are present in all segments of the human gastrointestinal tract 
(De Maeyer, Lefebvre et al. 2008). They are expressed on enterochromaffin cells, 
IPANs, interneurons, and efferent neurons of the myenteric plexus as well as smooth 
muscle cells. Thus, their activation can affect all components of the peristaltic reflex.  
 In some species, such as humans, there are inhibitory 5-HT4 receptors that are 
expressed on enterochromaffin cells, which mediate autoregulation of serotonin 
release (De Maeyer, Lefebvre et al. 2008). In addition, the activation of 5-HT4 
receptors on IPANs could either initiate or strengthen the peristaltic reflex. Of note, 5-
HT4 receptors are present on the efferent limbs of the peristaltic reflex, activation of 
which, on efferent myenteric cholinergic excitatory neurons, leads to enhanced 
acetylcholine release, and thus an increase in contraction. This is likely the 
predominant mechanism through which 5-HT4 receptor agonists affect 
gastrointestinal motility. In therapeutic use, 5-HT4 receptors have the potential to be 
activated by a wide array of compounds from varying classes of drugs. 
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Metoclopramide, a prokinetic drug of the benzamide class, was found to be a ligand 
for both 5-HT3 and 5-HT4 receptors. It played a large role in the discovery of potent 
and selective 5-HT4 receptor drugs.  
 Briefly, there are 5-HT4 receptors in the heart as well. They are expressed in 
the atria and ventricles, though at low densities (De Maeyer, Lefebvre et al. 2008). 
Thus, many of the effects of 5-HT4 receptor agonists are lesser when compared with 
serotonin. Some of these effects include an increase in contractile force, an increase in 
the onset of muscle relaxation, and an increase in heart rate. That there is a lower 
efficacy for the 5-HT4 receptors in the heart as compared with serotonin is relevant 
because of the association between 5-HT4 receptor agonists and cardiovascular 
events. No evidence was found to substantiate these claims with the use of renzapride 
and prucalopride. 
 5-HT4 and Opioid receptors:  
 As stated above, 5-HT4 receptors seem to have a hand in motility in the gut. 
When acting in concert with delta-opioid receptor antagonists, there seems to be a 
synergistic effect in the stimulation of colonic propulsion. Endogenous opioid 
peptides, and selective opioid receptor agonists (d, k, and mu) decrease the velocity of 
fecal pellet propulsion in isolated segments of guinea pig colon, as reported by Foxx-
Ornstein and colleagues (Foxx-Orenstein, Jin et al. 1998). They also reported that 
selective antagonists increased the velocity in a dose-dependent manner, where it was 
indicated that there was a preferential involvement of d-opioid receptors. 5-HT4 
agonists, which are known to increase propulsion, acted synergistically with the 
opioid d-receptor antagonist naltrindole. Opioid receptor agonists have distinct 
actions, both neural and muscular, in the gastrointestinal tract (Foxx-Orenstein, Jin et 
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al. 1998). These effects include contraction of smooth muscle cells of the circular 
layer, as well as inhibition of neuronal activity, which is reflected by a decrease in the 
release of excitatory and inhibitory neurotransmitters. 
 The inhibition of opioid peptide release facilitates the descending phase of the 
peristaltic reflex, and thus enhances intestinal propulsion. Studies into peristaltic 
activity using the opioid antagonists naloxone and norbinaltorphimine showed an 
increase in peristaltic contractions. However, parenteral or oral administration of 
opioid agonists gives rise to rhythmic, uncoordinated, non-propulsive muscle 
contractions, which is likely mediated by the inhibition of the release of inhibitory 
neurotransmitters. Foxx-Ornstein and colleagues showed that selective 5-HT4 
receptor agonists can initiate peristaltic activity through activation of intrinsic sensory 
calcitonin gene related peptide neurons, which are normally activated by the serotonin 
released by enterochromaffin cells (Foxx-Orenstein, Jin et al. 1998). In addition, they 
reported that studies in pellet propulsion in isolated segments of guinea pig colon 
showed that serotonin and 5-HT4 receptor agonists increased the velocity of 
propulsion in a dose-dependent manner.  
Inflammatory Bowel Disease:  
 Inflammatory bowel disease (IBD) is a disorder marked by chronic intestinal 
inflammation. Its cause is unknown to date and is composed of 3 entities: Crohn’s 
disease (CD), ulcerative colitis (UC), and Inflammatory bowel disease unclassified 
(IBDU). UC and CD are chronic relapsing inflammatory disorders which affect the 
gastrointestinal tract. They have a progressive and destructive nature and, therefore, 
can cause various complications including stenosis, abscesses, fistulas, extra-intestinal 
manifestations and colitis-associated neoplasias and cancer.  
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  While the pathophysiology of IBD is not well understood, there are many 
hypotheses about its origin, such as an impairment in the mucosal barrier, commensal 
microbe dysbiosis, persistent pathogenic infection, and immune dysregulation. 
Individuals with a genetic susceptibility to IBD are exposed to a number of 
environmental factors, including diet and lifestyle, which can then induce an immune 
response that impairs the mucosal barrier and elicits chronic inflammation (Silva, 
Rodrigues et al. 2016). IBD occurs in the gastrointestinal tract, which houses the 
body’s largest component of the immune system. The innate and adaptive immune 
systems are balanced in complex interactions with intestinal microbes under normal 
conditions. Also, gastrointestinal tract is in a critical position as it is the frontier of the 
innate immune system (Kim and Cheon 2017). The inner lining of the intestine works 
as a barrier to defend the host from harmful pathogens, as well as an area where 
interactions with commensal microorganisms can occur. These interactions are 
modulated carefully by the intestinal immune system, and they contribute to 
homeostasis. When intestinal homeostasis is disrupted, IBD can arise for a variety of 
reasons.  
 IBD is a multi-faceted immune-mediated disorder that is characterized by 
chronic inflammation of the intestine. The clinical characteristics of IBD include 
hemorrhagic diarrhea, abdominal pain, tenesmus, anorexia and weight loss (Silva, 
Rodrigues et al. 2016). The severity of symptoms can vary, from mild to severe, and 
patients that do not response to clinical management and have complications, 
generally require surgical intervention. Their differences lie in the location and the 
depth of the inflammation, as well as the complications and prevalence that can occur. 
It is currently believed that a disturbance of the immune system and/or an imbalance 
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in interactions with microbes leads to the rise of chronic intestinal inflammation upon 
environmental triggers of genetically susceptible hosts.  
 Ulcerative colitis and Crohn’s Disease are chronic, relapsing, and remitting 
conditions for which no permanent cure exists, and from which long-term morbidity 
can result (M’Koma 2013). UC tends to affect the colon and is confined to the 
mucosal and submucosal compartments. CD, however, can involve any part of the 
gastrointestinal tract, from the oral cavity to the anus, and can involve all layers of the 
gut (M’Koma 2013). While the factors which contribute to the development of IBD 
remain largely unknown, IBD has long been considered a problem of Western 
societies, where the Western lifestyle contributes a great deal to their pathogenesis. 
IBD is most prevalent before age 20, between 20 and 30, as well as in the 60-70 age 
group (M’Koma 2013). 
 UC and CD are distinguished from each other as UC is centered in the distal 
colon, perineal disease, fistulas, histologic granulomas, and full-thickness as opposed 
to a largely mucosa-submucosa limited disease. In CD, granulomas are evident in up 
to 50% of patients, and fistulas are evident in up to 25%. While IBD susceptibility 
genes have been identified, such as NOD2 gene variants, there also have been 
advances in defining environment risk factors that suggest smoking, oral 
contraceptives, diet, appendectomy, breast feeding, antibiotics, vaccination, infection, 
and childhood hygiene may be involved (Loftus , Jess, Riis et al. 2005, Gaya, Russell 
et al. 2006, Halfvarson, Jess et al. 2006, Molodecky and Kaplan 2010).  
 IBD is thought to arise from an interaction between a genetically susceptible 
host and environmental factors that influence the normal gut microbiota and trigger an 
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abnormal mucosal immune response. Recent data (Chouraki, Savoye et al. 2011, 
Jakobsen, Paerregaard et al. 2011) suggest that children and adolescents show a high 
incidence of IBD. About 25-30% of patients diagnosed with CD, and 20% of patients 
diagnosed with UC, present symptoms before age 20. In IBD, a dysfunctional 
interaction between the gut microbiome and the mucosal immune system occurs, 
which has the potential to cause the loss of intestinal immune tolerance through 
overreaction of effector T-cells which react against common microbial antigens. One 
of the myriad of mechanisms that affect host inflammatory reactions is associated 
with short-chain fatty acids (SCFAs), which are produced by specific types of colonic 
bacteria (Silva, Rodrigues et al. 2016). In IBD, the level of SCFA is significantly 
decreased, which may be a factor in compromising the intestinal and immune 
homeostasis. 
 In UC, goblet cell depletion and an associated reduction in the mucus layer are 
characteristic findings. Kim and colleagues noted evidence (Peltekova, Wintle et al. 
2004, Jung, Park et al. 2017) showing that single nucleotide polymorphisms (SNPs) in 
the organic cation transporter (OCTN), which is responsible for the transport of 
organic cations across the cell membrane, were associated with susceptibility to CD. 
In addition, Intestinal Epithelial Cells (IECs) play a role as communicator between 
pathogens and the lamina propria. Generally, only a small number of bacteria can 
move into the intestinal epithelium. This is a method by which the intestinal mucosal 
immune system samples antigens and conducts immune surveillance essential for the 
host’s immune homeostasis. Once the integrity of the intestinal epithelial layer is 
compromised, however, an influx of intestinal contents and/or a burden of 
microorganisms is thought to give rise to, and maintain, an inflammatory response 
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considered to be one mechanism underlying IBD (Sartor 2006). In example, 
Hermiston et al showed in an animal model where the barrier function of the intestinal 
epithelial layer is reduced, as is seen in mice with a dominant negative N-cadherin 
mutation, IBD-like enteritis is seen.  
 In IBD, large-bowel involvement is typical, and may result from UC, or 
IBDU, and possibly from the subset of non-complicated CD with an isolated colonic 
localization. In terms of classification of disease, however, the spread of the disease to 
other gastrointestinal segments leads, definitively, to the diagnosis of CD. It should be 
noted though, that one-third of patients with CD exhibit the disease in a purely 
colonic fashion, whereas two-thirds have a non-restrictive, non-penetrating disease 
behavior at the time of diagnosis, which shares many similarities with UC. In CD, 
disease localization appears to be a stable trait, with a spread to the small bowel in 
only a small number of cases. IBD restricted to the colon which cannot be classified 
as CD or UC is termed “inflammatory bowel disease unclassified” or IBDU. IBDU 
has been associated with a worse prognosis than UC due to the higher frequency of 
relapse, an increased risk of colon cancer, and less favorable outcomes following ileal 
pouch-anal anastomosis. There is, however, few data available on the prevalence of 
IBDU. A study done by Meucci et al of adults in European countries show the 
prevalence of IBDU varying from 3 to 7 per 100,000 inhabitants. The diagnosis of 
IBDU comprises 5-15% of new IBD cases. However, IBDU tends to represent a 
provisional diagnosis, as many studies (Meucci, Bortoli et al. 1999, Carvalho, 
Abadom et al. 2006, Tremaine 2012, Magro, Langner et al. 2013) show that 80% of 
those diagnosed with IBDU will be reclassified to CD or UC within 8 years. Though 
it should be noted that in a subset of cases, IBDU is the most accurate diagnosis.  
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 The integrity of the epithelial layer allows the bacteria of the intestinal lumen 
to communicate with the immune system. The mucous layer is the first physical 
barrier on the mucosal surface. It is formed by inner and outer layers produced by 
polymerization of gel-forming mucins which are secreted by Goblet cells. The inner 
layer is sterile, while the outer layer is inhabited by commensal bacteria which 
consume nutrients such as mucin glycan. Next, the intestinal epithelium is the second 
barrier, and considered the second line of defense against bacterial invasion. It is 
composed of enterocytes and specialized epithelial cells called Goblet cells and 
Paneth cells. Intestinal epithelial cells (IECs)s also play a role in the mucosal barrier, 
as they prevent the influx of antigens, as well as invasion of both pathogens and 
commensal bacteria. The IEC is made up of many different cells, such as enterocytes, 
goblet cells, neuroendocrine cells, Paneth cells, M cells, and epithelial resident 
intestinal stem cells (Kim and Cheon 2017). IECs structurally constitute crypts and 
villi, with a columnar cell lining containing a tight junction. IECs also secrete mucus 
containing anti-microbial peptides. They separate intra-luminal pathogens from the 
sub-epithelial lamina propria.  
 A mucus layer covers the outer epithelial surface which serves as a protection 
for the mucosa. This mucus layer is comprised of glycosylated mucin from the goblet 
cells, and defensins from the Paneth cells and IECs. A critical component of mucin is 
encoded by Muc2 and, when deleted, spontaneous colitis has been noted in mice. One 
study, conducted by Heazlewood et al, showed that aberrant mucin production was 
accompanied by endoplasmic reticulum stress. IECs are key in the maintenance of 
tolerance toward alimentary antigens and commensal bacteria. In addition, IECs 
activate both the innate and adaptive immune responses. IECs, in the protection of the 
28 
 
mucosal barrier, present tight junctions, and produce mucins and defensins. In 
addition, IECs express toll-like receptors (TLRs) and nucleotide oligomerization 
domain receptors (NOD), which are pathogen sensitive innate immune receptors 
(Silva, Rodrigues et al. 2016). IECs can also produce chemokines and cytokines to 
enlist immune cells. Thus, TLR signaling pathways can produce pro-inflammatory 
cytokines like IL-12 and 6 by way of IECs and can help to keep the epithelial barrier 
intact (Bamias and Cominelli 2007, Hisamatsu, Kanai et al. 2013). An impairment in 
the epithelial barrier can lead to an increased permeability within the intestine, which 
has been observed in CD and UC (Salim and Soderholm 2011). As noted by Silva et 
al, some Genome Wide Associative Studies (GWAS) suggest that this might represent 
a primary pathogenic mechanism in IBD (Tontini, Vecchi et al. 2015).  
 IBD is associated with intestinal dysbiosis, or the imbalance of functions of 
gut microorganisms which impair the host microbe and immune homeostasis 
(Miyoshi and Chang 2017). The human gut contains roughly 1011-1012 
microorganisms per gram of intestinal lumen content, which are called commensal 
bacteria. These commensal bacteria can be beneficial to the host under normal 
conditions, as they aid in the protection of the intestinal epithelium and digestion 
(Sartor 2006, Sung and Park 2013). Normally, many commensal bacteria are essential 
in the protection of intestinal homeostasis. These commensal bacteria affect nutrient 
provision, which is crucial, as well as the development of the immune system, and 
modulation of energy metabolism. Commensal bacteria consist mostly of gram-
negative bacteria, like Bacteroidetes, and gram-positive bacteria, like Firmicutes. 
Other phyla consist of Proteobacteria, Actinobacteria, Fusobacteria, and 
Verrucomicrobia (Eckburg, Bik et al. 2005, Cho 2008). These mucosae associated 
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phyla show a reduction in number and diversity in individuals with IBD when 
compared to healthy individuals (Eckburg and Relman 2007, Frank, St Amand et al. 
2007, Abraham and Cho 2009). 
 Individuals with genetic susceptibility are exposed to any number of 
environmental factors, like diet and lifestyle, which can then induce an immune 
response which alters the intestinal microbiota and can impair the mucosal barrier 
(Devkota, Wang et al. 2012, Hisamatsu, Kanai et al. 2013, Ward, Pierre et al. 2016). 
Devkota et al showed that a diet which does not change the intestinal microbiota is 
crucial in the prevention of IBD. They showed that there was an increase in 
prevalence of experimental UC when colitis-susceptible mice (see below) were fed 
with food containing high levels of saturated fat. This diet promoted the growth of a 
commensal bacterium called Bilophila wadsworthia (Silva, Rodrigues et al. 2016). 
The reported growth was likely due to changes in composition of bile acids caused by 
the high intake of saturated fat, which lead to dysbiosis. In addition, von Mutius et al 
suggested that exposure to commensal bacteria during childhood has potential 
protective effects against the development of IBD, as it is critical to stabilize immune 
tolerance (M’Koma 2013). 
 While these commensal bacteria are helpful, they can be harmful under certain 
conditions. Some evidence has been presented, which shows that antibiotic treatment 
is effective in some IBD patients (M’Koma 2013). In addition, IBD patients have 
been shown to have increased action against indigenous bacteria. Mononuclear 
phagocytes, like macrophages and DCs, are responsible for a lack of immunological 
response to the commensal bacteria, which is key in the maintenance of gut 
homeostasis. The microbiome is key in the production of pro-interleukin (IL)-1beta in 
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resident mononuclear phagocytes. When the epithelial barrier is intact, commensal 
bacteria cannot cause the maturation of pro-IL-1beta into its biologically active, 
mature counterpart. As a result, a state of low response is maintained (Strugnell and 
Wijburg 2010). The first defense against invading microorganisms and other 
potentially harmful agents is called innate immunity. Its response is activated mere 
minutes after invasion from microorganisms and can last a few hours. It has no classic 
immunological memory (Medzhitov and Janeway 2000).  
 Aside from innate immunity, adaptive immunity also plays an important role 
in disease. T-cells regulate the immune response from IBD and proliferate in the 
peripheral blood. They differentiate when stimulated by the presence of antigens.  
There is a subtype of T-cells, called T-helper cells (Th) that assist in the adaptive 
immune response. Some important Th cells are Th1, Th2, Treg, and Th17. Each 
subtype of Th cells has immune functions relevant to the adaptive immune response. 
Th1 cells aid in the elimination of pathogenic agents, and Th2 cells manage allergic 
reactions, as well as aiding in the protection from parasites. It is important to note that 
Th1 cells are important in the secretion of pro-inflammatory cytokines, like IL-1, IL-
2, and IL-12. Next, Th17 cells aid in the removal of exogenous bacteria and fungi, 
and lastly, Treg cells promote the repair of tissues. While these cells aid in the 
adaptive immune response, alterations in their proliferation can have profound 
negative effects (Silva, Rodrigues et al. 2016) With alteration, these cells can cause a 
large increase in chemo- and cytokines, which would cause a worsening of the 
inflammatory process, or the maintenance of it. Once antigens have been identified in 
gut-associated lymphoid tissue (GALT), Th1 and Th2 cells are activated. In addition, 
B lymphocytes mature, and can produce antigen-specific immunoglobulins. 
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Experimental Animal Models of Colitis:  
DSS:  
 Dextran sodium sulfate (DSS) induced colitis is one of the most commonly 
used models of colitis. DSS is a water soluble, negatively charged sulfated 
polysaccharide, with a varied molecular weight, which ranges from 5 to 1400 
kilodaltons (kDa). The most severe colitis arising from this model results from the 
administration of between 40-50 kDa of DSS into the drinking water of the animal 
(Chassaing, Aitken et al. 2014). While the mechanism through which DSS induces 
intestinal inflammation characteristic of colitis is not clear, it is likely due to damage 
of the epithelial monolayer that lines the large intestine. This allows the dissemination 
of proinflammatory intestinal contents, such as bacteria and their products, into the 
underlying tissue (Chassaing, Aitken et al. 2014). The popularity of the model stems 
from its rapid onset, its simplicity, the reproducibility, and its controllability. Of note, 
in DSS colitis, unlike in human IBD, T and B cells are not required to develop the 
colitis this model produces (Chassaing, Aitken et al. 2014).  
 Once administration of DSS has begun, the animals used, usually mice, are 
typically monitored daily for changes in weight, and the presence of blood in their 
feces. In addition, any mice that lose 25-30% of their starting weight should be 
euthanized. Also, in this model the severity of disease and mortality can be variable, 
so a sufficient number of animals should be used (typically 5-10) (Chassaing, Aitken 
et al. 2014). Chassaing et al also reported that the colitis induced by DSS tends to 
occur gradually in younger mice as compared to older mice. This is likely due to 
younger mice having a lower demand for food and as such, water intake. As water 
intake is crucial for DSS, being that DSS is put into the water supply, this would make 
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sense that the younger mice develop the disease at a slower rate. The optimal age for 
best results in the DSS model range from 6-8 weeks. While both male and female 
mice develop the colitis which DSS induces, males develop more rapidly, more 
significantly, and more aggressively than their female counterparts (Chassaing, 
Aitken et al. 2014). It should also be noted that mice, regardless of sex, kept in a 
germ-free environment either do not develop colitis, or have a very mild onset.  
 DSS causes damage to the gastrointestinal tract because it carries has highly 
negative charged sulfate groups. This is toxic to colonic epithelia and induces 
erosions that ultimately compromise barrier integrity. This results in an increase in 
colonic epithelial permeability. Also, DSS has an anticoagulant property, which 
aggravates intestinal bleeding. DSS-induced pathology tends to be contained within 
the large intestine, more specifically the distal colon, for unknown reasons. How DSS 
passes through the mucosal epithelial cells has yet to be elucidated, but Laroui et al 
suggest that the colitis induced by DSS is formed by nano-lipocomplexes with 
medium-chain-length fatty acids (MCFAs) within the colon (Laroui, Ingersoll et al. 
2012). In addition, the specificity of DSS for the colon could possibly be a function of 
the absorption of water and electrolytes in the presence of bacteria.  
 In terms of action, administration of DSS induces signs of colitis as quickly as 
1 day after treatment, as shown by changes in expression of tight junction proteins, 
(Poritz, Garver et al. 2007) and through an increase in the expression of 
proinflammatory cytokines (Yan, Kolachala et al. 2009). The modest initial effects are 
then followed by an increase in more drastic symptoms such as an increase in 
intestinal permeability, severe bleeding, and, if severe enough., mortality. 
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 Colitis induced by DSS appears to have similar clinical and histological 
features as human IBD, in particular UC. Acute changes in the histology of the colon 
can be induced through relatively short exposure to a high dose of DSS (4-7 days) 
(Chassaing, Aitken et al. 2014). Whereas chronic lesions can be brought forth by 
continuous treatment of a low dose of DSS, or through cyclical application. The acute 
histological changes are associated with symptoms like weight loss, diarrhea, blood in 
the feces, a hunched back, and in severe cases, death (Chassaing, Aitken et al. 2014). 
Common histological changes brought forth by DSS can include the depletion of 
mucin and goblet cells, the erosion of the epithelium, and ulceration. In addition, DSS 
induced colitis causes an influx of neutrophils into the lamina propria and submucosa. 
The trans-epithelial migration of neutrophils, also called cryptitis, and the extensive 
migration of neutrophils through mucosal epithelium and into the crypt lumen, called 
crypt abscess, are most commonly associated with human IBD. These effects are not 
as common in DSS colitis but have been reported. In chronic DSS colitis, there is an 
infiltration of mononuclear leukocytes, the disarray of crypt architecture, and increase 
in the gap between the base of the crypt and the muscularis.  
TNBS: 
 In addition to the DSS model of colitis, the Trinitrobenzenesulfonic acid 
(TNBS) model of colitis is also commonly used. Its administration is combined with 
ethanol, at a dose of 100 mg/kg, intra-rectally. The use of ethanol is for the effective 
disruption of the intestinal barrier, and to enable the interaction of TNBS with colonic 
tissue proteins. TNBS is a classical contactant and acts as a hapten. Little et al in 1966 
suggested that, when coupled with proteins with a high molecular weight, TNBS can 
bring forth significant immunologic responses, causing those proteins to elicit an 
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immune response from the host’s immune system (Little and Eisen 1966). The 
combination of TNBS and ethanol requires only a single administration to lead to the 
development of excessive cell mediated immune response, which is characterized by 
Th1 inflammation (Antoniou, Margonis et al. 2016). Once colitis has been induced, 
the animals develop many manifestations of acute colitis, such as inconsistent 
formation of feces, and bloody diarrhea. Through intracolonic administration of the 
combination, a severe illness is induced characterized by bloody diarrhea, and a large 
decrease in weight within the first week. Following this, the weight increases but the 
diarrhea persists (for up to 2 weeks). Antoniou et al reported that, once TNBS was 
introduced to animals, there was a significant weight loss, the mean being 10%, as 
well as the development of liquid, bloody feces (Antoniou, Margonis et al. 2016). The 
control animals, which received saline, remained healthy, and gained weight.  
 The weight loss seen in this model of colitis is caused by the effects of TNBS 
itself within the gut, such as diarrhea and possibly a reduction in fluid absorption. In 
addition, a systemic inflammatory response could also have a role. Other signs of 
general deterioration, although non-specific, include piloerection of fur and a decrease 
in the movements of the TNBS treated animals. The onset of the symptoms and their 
severity, however, is variable, and can depend on the species of animal, the strain of 
animal, and the dose of ethanol and TNBS administered. Prior to induction of TNBS 
colitis, the animals are fasted, from 12-24 hours. Then, the mice are anesthetized. 
Once anesthetized, the TNBS, dissolved in ethanol, is administered intrarectally. 
Following administration, the animals are maintained in a head down position so as to 
prevent expulsion of the administered TNBS, as well as to achieve an even 
distribution. As is evident in the literature, the dosing of the TNBS and ethanol is 
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varied. Various researchers use a range of between 50 and 150 mg/kg body weight. 
Morris et al who established the TNBS model, report an ideal dosage of 100 mg/kg 
(Antoniou, Margonis et al. 2016). Mice that receive ethanol only show a normal 
appearance, with no histological abnormalities. A dose of 50mg/kg showed a low 
level of colitis, whereas a dose of 150 mg/kg had a mortality rate of between 20 and 
30%, as associated with high to severe levels of colitis. Antoniou et al reported that 
death resulted primarily from excessive inflammation, and sometimes perforation, as 
shown in postmortem autopsy (Antoniou, Margonis et al. 2016). In the 100 mg/kg 
dosage, most of the mice (90% as reported by Antoniou et al) showed thickening of 
the colon, focal hyperemia, and intestinal ulcerations, in roughly 65% of the treated 
animals. It should be noted that TNBS colitis is somewhat variable, and the disease 
level can vary amongst the mice. Some mice show low levels of inflammation, 
whereas others may suffer lethal levels, or could die within 48 hours of TNBS 
treatment. Of note, during the course of disease, mucosal edema, distortion of the 
crypts, and formation of abscesses can occur over the course of the disease. In 
addition, there is the potential for hemorrhagic ulcerations. Through histological 
examination, Antoniou et al reported the infiltration of leukocytes and erythrocytes 
into the mucosa and submucosa was shown in the first week. Within the next two 
weeks, the mucosa, submucosa and muscularis propria were infiltrated by neutrophils, 
macrophages, and lymphocytes. In addition, they reported granuloma-like structures 
and fibroblasts.  
 TNBS induced colitis is a commonly used animal model which shares many 
properties with Crohn’s disease in humans. Its advantages include its reproducibility, 
technical simplicity, and a low cost. This model can be used in rodents and guinea 
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pigs and can have significant strain-dependent differences. TNBS induced colitis is a 
strong tool with which to study immunopathogenesis, as well as possible treatments 
for the disease.  
  
T-Cell Transfer: 
 Briefly, in addition to the chemically induced models mentioned, DSS and 
TNBS colitis, there is the T-cell Transfer model of colitis. This model of colitis builds 
on the foundation that T lymphocytes play a large role in the onset of colitis. T 
lymphocytes recognize antigens from antigen presenting cells and generate targeted 
immune responses to enteric bacteria or intestinal self-antigens (Bramhall, Flórez-
Vargas et al. 2015). This model utilizes naïve T cells from wild-type mice and 
transfers them to mice who genetically lack T and B cells (such as mice with Severe 
Combined Immunodeficiency (SCID) or RAG 1/2). Colitis in this model occurs as a 
result of enteric antigen-drive activation, polarization, and homeostatic expansion of 
the naïve T-cells used (Ostanin, Bao et al. 2009). These helped produce cells that aid 
in the induction of colitis like Th1 and Th17.  Colitis symptoms occur 2 weeks post 
transfer, and pancolitis is present at 4 weeks. Unlike in DSS and TNBS colitis, this 
model requires a more complex and labor-intensive protocol. This is due to extraction, 
isolation, purification, and injection of the T cells. Also, there are factors that affect 
the resulting colitis such as the strain of animal, the number and viability of the T-
cells that are transferred and the presence, if any, of B cells in the animals to which 




IL-10 Knockout:  
 Interleukin-10 (IL-10) is an anti-inflammatory cytokine. It was initially 
described as a T helper derived cytokine, though it is now widely accepted that it was 
not restricted to certain subsets of T-cells; indeed, it is produced by almost all 
leukocytes (Iyer and Cheng 2012). The major sources of IL-10 include T helper cells, 
monocytes, macrophages, and dendritic cells. Also, a myriad of other immune 
effector cells has the capability of producing IL-10 in specific contexts. Such cells 
include B cells, cytotoxic T cells, NK cells, mast cells, and granulocytes like 
neutrophils and eosinophils (Iyer and Cheng 2012). As an anti-inflammatory cytokine, 
its immunosuppressive activity is mediated by a heterodimeric IL-10 receptor. While 
the IL-10 receptor is expressed to varying degrees in many cell types, it seems that 
monocytes and macrophages are the primary target. Binding of IL-10 to its receptor 
leads to large changes in the expression of immunomodulatory genes, which then 
causes the inhibition of proinflammatory mediators. IL-10 can directly or indirectly 
inhibit the development of some cells, as well as suppressing some cell and allergic 
responses. It can also positively enhance the activation and proliferation of certain 
immune cells types such as mast cells, CD8+ T cells, NK cells, and B cells.  
 Some initial studies showed that deficiencies in IL-10, by way of disruption of 
the IL-10 gene, or signaling by blockade of the receptor, most intracellular infections 
are better controlled, or cleared faster. Cessation of signaling leads to enhanced 
survival post infection and is associated with enhanced adaptive immune response. In 
addition, in the case of some parasitic infections, such as Y. Pestis, IL-10 is a 
biomarker for poor disease outcome (Iyer and Cheng 2012). The impairment of IL-10 
signaling has effects in many experimental disease models, such as various infection 
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models, as well as inflammatory bowel disease, rheumatoid arthritis, multiple 
sclerosis, and others. Many pathogens have evolved mechanisms through which they 
selectively up-regulate IL-10 during infection, potentially create a more favorable 
environment. One such example is Toxoplasma gondii, which can shut down TLR4-
mediated LPS signaling in such a way that blocks TNF-alpha expression but allows 
IL-10 to be produced (Iyer and Cheng 2012). However, it should be noted that while 
initially beneficial to the host, the absence of IL-10 in the long term is very 
detrimental. Such prolongation or enhancement of inflammatory cytokines, with no 
cessation, can lead to septic shock by viral, bacterial, or fungal infection. As 
inflammatory molecules have the potential to be potent activators of cell death, the 
increase of IL-10 levels can moderate the extent of apoptosis caused by the response 
to the infection. An example of this is in a model of Chlamydia pneumoniae. Bacterial 
clearance is enhanced by the absence of IL-10, and mice also develop severe 
inflammation, and elevated levels of apoptosis. Iyer et al reported that, in this model, 
blocking the action of CD8+ T-cell derived IL-10 causes enhanced pulmonary 
inflammation, and lethal injury. As such, this indicates that resolution of infection 
needs a coordinated response by which initial pro-inflammatory mechanisms clear the 
pathogen, and then are limited by IL-10 before negative effects can occur.  
 With the understanding that IL-10 is an important mediator of the 
inflammation response, the IL-10 knockout (IL-10 KO) model of colitis demonstrates 
the effect on mice of the loss of this important cytokine. This model of colitis was 
first generated in 1993 by Kuhn et al. Kuhn et al using a targeted mutation which 
disrupted the IL-10 gene by replacing a 500-base pair fragment of exon 1 with a 
termination codon, and a neo expression cassette, and by introducing a termination 
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codon into exon 3 (Keubler, Buettner et al. 2015). IL-10 deficient mice spontaneously 
develop colitis after weaning as IL-10 is a key gut mediator and essential for the 
maintenance of intestinal homeostasis. The colitis that is seen in this model arises 
from an aberrant response of CD4+ Th1-like T-cells in addition to an excessive 
secretion of IL-12, IL-17, and Interferon gamma (IFNg), which are all pro-
inflammatory cytokines. 
 The colitis seen in this experimental model can be reversed by treatment with 
recombinant IL-10 (Keubler, Buettner et al. 2015). The IL-10 model of colitis is 
highly regarded because mice are found to have histological findings that are akin to 
those found in human IBD, and no chemical treatment is necessary. In this model, 
inflammatory cells infiltrate the lamina propria and submucosa, the epithelium is 
disrupted, mucin is depleted, the formation of crypt abscesses and cryptitis occurs, as 
well as the formation of ulcers and the thickening of the intestinal wall. The 
inflammation seen in this model is initially driven by a pro-inflammatory Th1 T-cell 
response, and thus can be ameliorated by the systemic administration of anti-IL-12p40 
(Keubler, Buettner et al. 2015). Stimulation of the mucosal immune system by 
commensal microflora is necessary for the colitis seen in this model. As such, mice 
contained in a germ-free environment do not develop colitis, unless transferred from a 
germ-free environment to a pathogen-free environment. It should also be noted that in 
the IL-10 experimental model of colitis, the onset of colitis can be delayed using 
antibiotics, further suggesting that resident bacteria are necessary for the development 
of colitis in this model. In addition, Alan Sher and his colleagues showed that, in germ 
free IL-10 deficient mice, the bacteria Helicobacter hepaticus is responsible for the 
rise of colitis (Kullberg, Ward et al. 1998). 
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 Importantly, while there has been efficacy shown in IL-10 recombinant 
therapy in preclinical models, recombinant IL-10, in practice, has shown weak 
therapeutic potential (Davidson, Leach et al. 1996, Duchmann, Schmitt et al. 1996, 
Tomoyose, Mitsuyama et al. 1998). There are several factors which contribute to the 
failure of recombinant IL-10 therapy in clinical trials. The first of these is that 
systemic administration might not be sufficient enough to deliver IL-10 to mucosal 
inflammatory sites upon which it can exert anti-inflammatory functions. Second, IL-
10 impairment is essential for the development of colitis in the IL-10 deficient mouse. 
Specifically, it is the impairment of the IL-10 derived from CD4+, from T-regulatory 
cells, not B-cells, that is necessary (Murai, Turovskaya et al. 2009) 
Specific Aim:  
 Approximately 1-1.3 million people in the United States have an Irritable 
Bowel Disease (IBD). IBDs are classified as Crohn’s Disease and Ulcerative Colitis 
(UC). UC effects approximately 907,000 Americans today. It is characterized by 
inflammation of the colon, and the formation of ulcers. Unfortunately, treatment 
options are limited and ineffective in many individuals with IBD. Recent work 
performed in the Mawe laboratory has demonstrated that 5-HT4 agonists, acting in 
the colonic epithelium, could represent a novel and effective treatment for IBD.   
Spohn and colleagues demonstrated that 5-HT4 agonists, delivered by enema, 
attenuates the development of colitis, and accelerates the healing of, established 
colitis. These studies were performed using the trinitrobenzene sulfonic acid (TNBS) 
and dextran sulfate sodium (DSS) models of colitis, both of which involve chemical 
agents delivered to the lumen of the colon. 
41 
 
 IBD is thought to develop because of an imbalance in the mucosal immune 
response. Another experimental model of colitis, which involves an imbalance of 
mucosal immunity, is the interleukin-10 (IL-10) knockout mouse.  Since these mice 
lack the anti-inflammatory cytokine IL-10, colitis develops spontaneously without 
having to introduce exogenous chemicals to the lumen. In the proposed studies, we 
tested the hypothesis that intraluminal administration of a 5-HT4 agonist is protective 
in IL-10 KO mice. 
Aim 1. Test the hypothesis that treating IL-10 knockout mice with 5-HT4 receptor 
agonist will attenuate the development of colitis. We treated IL-10 knockout mice 
immediately following weaning. We used the disease activity index, histologic 
damage score, and Ki67 stained slides to judge the effect of 5-HT4 agonist and 
vehicle control on IL-10 knockout mice. We used the disease activity index to check 
the mice used for weight loss, presence of fecal blood, and stool consistency. We also 
used the histologic damage score to test for epithelial damage, ulcers, erosions, to 
look at crypt architecture and whether it is altered, and to see if the lamina propria has 
been infiltrated by monocytes and polymorphonuclear cells.  
This study tested the effect of 5-HT4 receptor agonists and their ability to attenuate 
the inflammatory actions of interleukin-10 knockout induced colitis. This study 
strengthened both previous data from the Mawe lab and our understanding on 5-HT4 
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CHAPTER 2: THE EFFECTS OF 5-HT4 RECEPTOR AGONIGISTS ON 
INTERLEUKIN-10 KNOCKOUT MICE 
Abstract: 
 Recent studies have demonstrated that activation of the 5-HT4 receptors in the 
colonic mucosa can exert healing and protective actions in experimental models of 
colitis. These actions include increased mucus secretion, increased epithelial 
proliferation, enhanced epithelial migration, and resistance to oxidative stress. Since 
these studies involved chemically induced models of colitis, the current investigation 
was conducted to test whether a protective action of 5-HT4 receptor stimulation could 
be detected in Interleukin-10 knockout (IL-10 KO) mice, which develop colitis 
spontaneously due to the absence of the anti-inflammatory cytokine, IL-10.  
 Upon weaning, the IL-10 knockout mice were separated into two groups: an 
agonist group and a vehicle control group. The agonist group received 1 mg/kg 
tegaserod in a vehicle consisting of 0.9% saline each day by enema of dimethyl 
sulfoxide (DMSO) in saline each day, while the control group received daily enemas 
of vehicle over the course of 21 days. The concentration of tegaserod utilized was the 
same as used in the study done by Spohn and her colleagues, so as to give a 
therapeutic dose of the drug but not to elicit potential adverse effects. Several 
outcome measures were used to assess the effectiveness of the treatment. To evaluate 
the severity of colitis, disease activity index (DAI) was monitored, and histologic 




 Administration of tegaserod by enema to the IL-10 KO mice had a significant 
protective effect on the treated mice. The DAI of agonist treated mice was 
significantly better than that of vehicle treated mice over time (p<0.001; 2-way 
ANOVA). Mice treated with vehicle had a more significant decline in health over 
time versus the agonists, with more blood present in feces and a looser/diarrhea-like 
consistency in stool. The histological damage score was also improved by 5-HT4 
agonist treatment (p<0.05, t-test). Sections of vehicle treated colons showed 
significantly greater damage, including epithelial erosions, the presence of 
polymorphonuclear cells, and abnormal crypt architecture (cryptitis), than those 
treated with the 5-HT4 receptor agonist tegaserod. During the 21-day course of the 
current investigation, there was no difference in survival between the two groups.  
 Collectively, these data, suggest that administration of the 5-HT4 receptor 
agonist tegaserod via enema to IL-10 KO mice has a greater healing and protective 
effect compared with vehicle treatment. We tested the hypothesis that treatment of IL-
10 knockout colitis with a 5-HT4 receptor agonist will attenuate the development of 
colitis and have healing and protective effects in the colons of the treated mice.  
Introduction:  
  Serotonin (5-hydroxytryptamine, 5-HT) is classically thought of as a brain 
neurotransmitter. However, most of the body’s serotonin is made and found in the 
gastrointestinal tract. Serotonin in the gut is responsible for many actions such as 
motility, mucus secretion, and chloride secretion from enterocytes. There are also a 
number of serotonin receptor subtypes found within the gastrointestinal tract, such as 
5-HT3, 5-HT4, and 5-HT7. While there haven’t been many studies conducted on how 
5-HT7 might function, there have been numerous studies, and drugs, detailing the 
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effects of 5-HT3 and 5-HT4 on the gastrointestinal tract. The 5-HT3 receptor is ligand 
gated, and antagonists at this receptor constitute its therapeutic effects. Drugs like 
ondansetron are used to combat nausea and vomiting that are commonly associated 
with cancer chemotherapy, radiation therapy, and surgery. 5-HT4 receptors, however, 
are G-protein coupled, and therapeutic drugs that act on these receptors are agonists. 
5-HT4 receptor agonists, like tegaserod and cisapride, were used to combat 
constipation-predominant Irritable Bowel Syndrome (IBS-C).  
 As 5-HT4 receptors have been shown to increase motility and have been 
proposed to have anti-inflammatory effects (Sung and Park 2013, Spohn, Bianco et al. 
2016), we proposed to test the hypothesis that administration of the 5-HT4 receptor 
agonist tegaserod will attenuate the development of colitis and provide protective and 
healing effects in the interleukin-10 (IL-10) knockout experimental model of colitis. 
While Spohn and her colleagues used the DSS and TNBS models of colitis, which are 
chemically induced experimental models of colitis, we proposed to use the IL-10 
knockout experimental model, which causes spontaneous colitis after weaning.  
 To assess the severity of the damage of colitis, and to determine the protective 
and healing effects of the tegaserod on the IL-10 KO model, we used a variety of 
tests. To determine the severity of the colitis, we used the disease activity index (DAI) 
and histologic damage score (HDS). The DAI measures the consistency of stool of 
each animal, and tests for fecal occult blood. The DAI was measured every day to 
obtain an accurate picture as to the progression of the disease. Typically weight is 
included in the DAI, but as the IL-10 deficient mice start off at lower weights, this 
metric was removed and utilized as a separate readout. The HDS was also used in the 
determination of the severity of the colitis and is a much more in-depth test. The HDS 
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uses hematoxylin and eosin (H&E) stained sections of colon to look at the structure 
changes of the crypts in the colonic epithelium, the presence of polymorphonuclear 
cells and mononuclear cells in the lamina propria, presence of granulomas, abscesses, 
erosions and ulcers, and epithelial damage. While the HDS gives a better picture of 
the colitis, it requires the euthanasia of the mice. In addition to these tests, 
immunostaining for the cell proliferation marker Ki67 was conducted. The Ki67 
staining was used to assess the cell proliferation in the sectioned colons and would 
denote the healing effects seen in administration of tegaserod. Our findings here 
suggest that in the IL-10 experimental model of colitis, 5-HT4 receptor agonists 
attenuate the development of colitis and provide healing and protective effects against 
the inflammation which characterizes colitis. 
Methods:  
  The mice used in this experiment were ordered from The Jackson Laboratory 
by Dr. Dimitry Krementsov. These mice, B6.129P2-IL10tm1Cgn/J, are also known as 
IL-10 knockout mice. We then bred the mice used for the study from those that were 
ordered. This model of mouse was generated in 1993 by Kühn and colleagues. 
Animal Preparation:  
 All experimental protocols were approved by the University of Vermont’s 
Institutional Animal Care and Use Committee. The mice were euthanized by either 




Assessment of Inflammation:  
 Severity of colitis in the mice was measured using the disease activity index 
(DAI). The DAI used measures presence of fecal blood, and consistency of stool in 
determining the severity of colitis in the mouse and is used as a measure of the health 
of the animal. The determination of fecal blood was done through HemOccult Single 
Slide testing slides and their developing chemical. The developing chemical, per 
Beckman-Coulter, is “an alcoholic/aqueous stabilised solution of hydrogen 
peroxide”. To utilize the HemOccult slide, a single fecal pellet was collected from 
each mouse. The fecal pellet was placed on one of the two testing windows on the 
card and smeared evenly. The developing chemical was applied to the feces, and if the 
developing chemical caused a blue color to show on the slide, the feces was 
HemOccult positive. The DAI uses a set of scores to denote the severity of the colitis 
seen in mouse as such: for the presence of fecal blood a score equivalent to 0 denotes 
no blood in the stool, a score of 2 for blood present through use of the developing 
chemical, and a score of 4 for gross bleeding. For the consistency of the stool a score 
of 0 denoted a normal stool sample. A score of 2 was softer than normal stool, and 
diarrhea received a score of 4. After 21 days, the mice were euthanized, and their 
colons were collected and fixed for immunohistochemistry.  
Histological Assessment of Inflammation:  
 Tissues from the euthanized IL-10 knockout mice were fixed by immersion in 
4% paraformaldehyde in 0.1M phosphate buffer overnight at 4°C. Tissue was then 
paraffin-embedded, sectioned at 10 μm, and stained with hematoxylin and eosin 
(H&E). The HDS is a scale that aids in the determination of changes in the crypt 
architecture, if any, infiltration of monocytes and polymorphonuclear cells into the 
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lamina propria, the presence of granulomas, erosions, and ulcers, as well as epithelial 
damage. The HDS used in the current study is the same as used in the work done by 
Spohn et al, which was co-created by her and a trained pathologist, Rebecca Wilcox. 
The slides for each mouse were scored blindly. Briefly, in determining the score for 
the HDS, we looked for epithelial damage, architectural changes, mononuclear and 
polymorphonuclear cells in the lamina propria, polymorphonuclear cells in the 
epithelium, and erosions and ulcers. In terms of epithelial damage, a score of 1 was 
noted by mild to moderate epithelial damage, and severe damage received a score of 
2. In terms of architectural changes, a score of 1 was noted as less than 50% disturbed 
architecture, and a score of 2 (extensive damage) was greater than 50% disturbed 
architecture. Mononuclear cell infiltration into the lamina propria was judged their 
presence, where a moderate increase received a score of 1 and a severe increase a 
score of 2. Polymorphonuclear cells were judged by how many were seen in a given 
field of view. If there were less than 3, but more than 0, this section received a score 
of 1. If there were 3 or more in a field of view, the score was a 2. Polymorphonuclear 
cells in the epithelium were judged in a few ways. A score of 1 noted that 
polymorphonuclear cells were found in the surface epithelium. A score of 2 denoted 
the presence of cryptitis (branching crypts), and a score of 3 was noted as crypt 
abscess. Lastly, if any ulcers or erosions were found, a score of 1 was received.   
Immunohistochemistry:  
 Unstained slides of sectioned colon from the agonist and vehicle treated mice 
were obtained. These slides were deparaffinized in xylene, and then 3 washes of 
ethanol at varying concentrations (100%, 95%, and 80%, respectively), and lastly a 
wash in water. Slides were blocked in 4% goat serum in 0.5% Triton-X in phosphate 
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buffered saline (PBS), slides were incubated in rat anti-mouse Ki-67 (1:100; 
eBioscience, San Diego, CA) in PBS with 0.5% Triton-X, rinsed, then incubated in 
goat anti-rat Cy3 antibody (1:1000; Jackson ImmunoResearch, West Grove, PA). 
Slides were counterstained with DAPI (1:10,000), a nucleic acid marker, to determine 
total number of cells. The slides were then covered and analyzed on a fluorescent 
filter microscope. First, the filter was set to so that the DAPI stained cells could be 
counted. This was noted as the total cell count per crypt. Then, the filter was switched 
so that the Ki67 stained cells were visible. These cells were counted and then 
calculated as a percent of the DAPI (the total number of cells). Ki-67 is a cell 
proliferation marker, and in this case is used to show wound healing effects of the 5-
HT4R agonist treatment. 
Results:  
 To test the effects of activation of the 5-HT4 receptor by agonist in colitis, the 
IL-10 experimental model of colitis was used. The IL-10 model was used because the 
colitis found in the IL-10 knockout mouse is characterized by histologic findings like 
that of human IBD (Keubler, Buettner et al. 2015). Specifically, these findings include 
crypt abnormalities, abscesses, erosions, and the infiltration of inflammatory cells into 
the lamina propria, which is consistent with the findings of the current study. In this 
experimental model of colitis, tegaserod was administered on the day of weaning, and 
each day after for 21 total days. The tegaserod was delivered intra-luminally via 
enema at a concentration of 1mg of tegaserod/ kg of body weight. The amount of 
enema given was 100 μL. At this time point, the mice exhibited signs of colitis, 
meaning that we were treating established colitis as opposed to waiting for the rise of 
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the disease. Colitis occurs in these mice was shown to occur as early as 4 weeks of 
age (Raza, Crothers et al. 2017). 
 The 5-HT4 receptor agonist tegaserod significantly decreased the DAI 
(p≤0.001, 2-way ANOVA, Figure 1) in the mice given agonist compared with those 
given vehicle. This finding suggests that the treatment was effective in improving the 
health of the mice over time, as compared to the vehicle treatment. The treatment also 
significantly improved the HDS (p≤0.05, t-test, Figure 2) in the mice treated with 
agonist. This shows that there was more protection in the mice given agonist than 
those given vehicle, as those given vehicle tended to have significantly higher HDS 
scores, and thus more damage to their colon. It also shows that there was attenuation 
of colitis in that there is less damage seen in the agonist treated mice in terms of 
epithelial damage, alteration in the crypt architecture, less infiltration of mononuclear 
cells and polymorphonuclear cells and no presence of erosion, which was seen in 
those treated with vehicle.  
 During the 3-week time course of the study, no significant difference in the 
survival pattern was detected between the two groups. Death was either as a result of 
the disease progression (before the treatment period was over) or at the time of 
euthanasia (21 days). Though this could likely be further elucidated with a longer end-
point since most of the mice in both groups survived the full three weeks.  
 Over the course of the study, the mice were weighed each day for their 
treatment period of 21 days. Wild type and heterozygous (IL-10+/+, IL-10 +/-, 
respectively) untreated mice were also weighed for comparison as they do not develop 
spontaneous colitis (Raza, Crothers et al. 2017). When a 2-way ANOVA was used to 
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compare all three groups at all time points, Tukey’s multiple comparison evaluation 
revealed differences between all three groups (P≤0.0001; Fig. 5).  However, when the 
weights of the mice were compared on their last day of treatment by 1-way ANOVA, 
there were no differences between the vehicle and agonist treated mice (P=0.42), but 
there were significant differences between the wild type untreated and agonist 
(P≤0.005, 1-way ANOVA, Figure 6) and between the wild type untreated and vehicle 
(P≤0.05, 1-way ANOVA, Figure 6).  
 Additional sections of colons from these studies were stained via 
immunohistochemistry for the cell proliferation marker Ki67 and counter stained with 
the nucleic DAPI. Once the slides were stained, they were examined under a 
microscope with fluorescent filters. From each colon section on the slide, 5 whole 
crypts were selected and the amount of DAPI stained slides were counted to get a 
total number of cells per crypt. Then, the amount of Ki67 positive cells were counted, 
and this was calculated as a percent. This examination was not blinded. We found that 
the mice treated with agonist had a significantly higher average percent of Ki67 
positive cells (p≤0.05; t-test, Figure 3) than did the vehicle. The agonist treated mice 
had roughly 30% of their total cells Ki67 positive, while the vehicle treated mice had 
just over 10%. The numbers seen from the agonist mice are similar to those reported 
by Spohn and her colleagues in their assessment of agonist treated mice in the DSS 
and TNBS experimental models of colitis. Due to Ki67 being seen in these mice, this 
shows that there is a wound healing effect, suggesting the protective effects of 




 This study was conducted to test the hypothesis that 5-HT4 receptor agonist 
administration in the interleukin-10 knockout experimental model of colitis would 
attenuate the development of colitis and have protective and healing effects. Our 
findings suggest that treatment with the 5-HT4 receptor agonist tegaserod attenuates 
the development of colitis and protects against the damaging effects of colitis.  
 The current study advances previous work done in the Mawe lab, by Spohn 
and her colleagues, in that in shows the efficacy of tegaserod, a 5-HT4 receptor 
agonist, in another model of colitis. Spohn and her colleagues used chemically 
induced experimental models of colitis (DSS and TNBS). The current study used the 
IL-10 knockout experimental model of colitis. While there are differences between 
the models, such as TNBS having findings closer to human Crohn’s colitis, each of 
these models have similarities to human IBD paradigms.  
 The current study further reinforces the significance of the data found by 
Spohn and her colleagues in that similar results are reported in a different model of 
colitis. The IL-10 model of colitis does not require the induction of disease as the 
mice are sick almost immediately after weaning. The data reported from the current 
study strengthens the results from the studies done by Spohn and her colleagues. In 
both cases, the DAI and HDS were significantly lower for the animals treated with 5-
HT4 receptor agonist than those treated with vehicle. In addition, in both cases, 
sections of colon stained via immunohistochemistry for the cell proliferation marker 
Ki67 showed wound healing in the mice treated with tegaserod. This wound healing 
likely results in the anti-inflammatory actions that are a result of 5-HT4 receptor 
activation. The anti-inflammatory effect seen because of intra-luminal administration 
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is likely due to a wound healing/immune regulatory effect and not an immune 
suppressant effect. This is evidenced in the immunohistochemistry staining of 
sectioned colons with the cell proliferation marker Ki67. The agonist treated mice saw 
a significant increase in cells which showed Ki67 than the vehicle treated mice. This 
means that tegaserod has a healing effect. Spohn et al used Caco-2 cells to further 
explore 5-HT4 receptor activation. Caco-2 cells are a common epithelial colorectal 
adenocarcinoma cell line. Caco-2 cells are used for in vitro study. Specifically, Spohn 
et al studied scratches made in Caco-2 cell monolayers and their treatment with 
tegaserod versus vehicle cultures. Spohn et al showed that 5-HT4 receptor stimulation 
enhances cell migration and provides resistance to oxidative stress-induced apoptosis.  
 While this study shows significance in many areas, like the DAI, HDS, and 
Ki67 stained sections of colons, there are limits. This study used mice bred in-house, 
as a constraint of time only a small number of IL-10 knockout mice were able to be 
obtained. As a result, this study would need more time to be able to breed more mice 
to increase the n values and determine more strongly the significance of the data. In 
addition, larger n values would strengthen the results already shown, that there are 
anti-inflammatory and wound healing effects that are caused by the activation of 5-
HT4 receptors by agonist.  
 There was no significant survival between the groups of mice, but this is likely 
due to the small n. It is likely that if the n value was increased the vehicle treated mice 
would have a lesser survival rate than the agonist treated mice due to the worsening of 
their disease, as shown by the results of the DAI and HDS tests, and in that they have 




 In addition, there is the need to perform further tests. Tegaserod is known to 
have other effects and so further trials with a 5-HT4 receptor antagonist would be 
necessary to elucidate the actions of tegaserod. While the trials performed by Spohn 
and her colleagues showed that antagonizing the 5-HT4 receptor does in fact inhibit 
the protective and attenuative actions seen in the activation of the 5-HT4 receptor by 
agonist in the DSS and TNBS experimental models of colitis, it would be prudent to 
perform similar agonist plus antagonist experiments in the IL-10 experimental model.  
 While this study reports low n values, it is prudent to note that significance, 
namely in DAI, HDS, and Ki67, were found. This significance can be further 
elucidated with more study and a higher n value. The advantage of increasing the n 
value of this study is to further elucidate the weight differences between the two 
treated groups, the survival in the treatment groups, and for further testing such as 
conducting an antagonist plus agonist group, and the use of a fecal lipocalin-2 ELISA.  
 The IL-10 experimental model of colitis was used because it has histologic 
features that are similar to those of human IBD (Chassaing, Aitken et al. 2014). IL-10, 
unlike DSS and TNBS colitis, causes colitis to occur spontaneously. IL-10 is an anti-
inflammatory cytokine which is responsible for resolving inflammation responses. It 
is also a key gut mediator, which along with its potent anti-inflammatory capabilities, 
could explain why spontaneous colitis arises from its deficiency. It should be noted 
that some gut microbiome is necessary for the development of colitis in the IL-10 KO 
model (Iyer and Cheng 2012). It has been shown by many studies (Iyer and Cheng 
2012, Bramhall, Flórez-Vargas et al. 2015, Kiesler, Fuss et al. 2015) where mice have 
IL-10 knocked out that being raised in a germ-free environment does not give rise to 
the development of colitis.  
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 Potential Mechanisms of Protection through 5-HT4 Receptor Activation: 
 There are a few ways in which the activation of epithelial 5-HT4 receptors can 
elicit the protective effects that have been described above. The fact that 5-HT4 
receptor agonists promote mucus secretion from goblet cells, and that 5-HT4 
receptors are found in the colonic epithelium likely means that the effects seen here 
are protective, not anti-immune. As shown in the immunohistochemistry data from 
Spohn et al and from the current study, mice treated with agonist in all three models 
of colitis (DSS, TNBS, and IL-10 knockout) showed Ki67 positive cells in around 
30% of their total cell count. This likely produces a wound healing effect. In addition, 
there is likely an anti-inflammatory effect as seen through the lower HDS and DAI 
scores seen in the mice given agonist. Histologically, healing from chronic 
inflammation is characterized by resolving abnormalities in crypt architecture, as well 
as resolving any infiltration of inflammatory cells (Neurath 2012). It should also be 
noted that after resolution of the chronic inflammation, there could still be features of 
sustained damage, such as a decrease in crypt density, and the presence of cryptitis 
(Price and Morson 1975, Rubio, Johansson et al. 1982). These criteria are met in the 
mice given agonist as they show less inflammatory cell infiltrate, they have less 
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Figure 1: The disease activity index scores as they progressed over time. The agonist 
had significantly lower scores (n= 3 for agonist, n=4 for vehicle, P≤0.001, 2-way 
ANOVA).  
 
Figure 2: The histologic damage score, which looks at crypt architecture 
abnormalities, presence of abscesses, granulomas, erosions, ulcers, and infiltration of 
polymorphonuclear and mononuclear cells. The agonist had significantly lower scores 
than the vehicle (n=3 for agonist, n=4 for vehicle, P≤0.0304, unpaired t-test). To the 
side of the graph are micrographs of a vehicle animal which was closest to the mean 
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HDS (top left, top right, bottom left) and an agonist animal closest to the mean HDS 
(bottom right). The mean for the vehicle was 7.3 and the closest scored vehicle treated 
animal was a score of 6.5. The mean for the agonist was 1.8 and the closest scored 
animal was a 2. All micrographs are shown at 10X on a microscope. The vehicle 
treated micrographs show elongation of crypts and branching crypts (cryptitis; top left 
micrograph), infiltration of inflammatory cell (top right micrograph), and the presence 
of polymorphonuclear cells in the lamina propria (bottom left). The agonist treated 
micrograph (bottom right) shows more normal crypts (not elongated), and no evident 
infiltration of inflammatory cells.  
 
Figure 3: Sectioned colons stained by immunohistochemistry for Ki67 positive cells 
to show cell proliferation. Sectioned colons were counter stained with 4',6-diamidino-
2-phenylindole (DAPI). A blue fluorescent filter was used to visualize DAPI. DAPI 
was counted in 5 crypts to obtain a total number of cells, and then the fluorescent 
filter was changed to red to visualize the Ki67 positive cells. The Ki67 positive cells 
were counted as a percent of the total cells (DAPI). The agonist had significantly 
more Ki67 positive cells than the vehicle (n=3 for agonist, n=4 for vehicle, P≤0.05, t-
test). Ki-67 positive cells were determined by their fluorescence in comparison to the 
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rest of the slide. Ki-67 positive cells can be clearly seen by their fluorescence and are 
more abundant in the agonist treated mice. The vehicle treated has fewer Ki-67 
positive cells.  
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Figure 4: The survival of both treatment groups. There was no significant different 
between the treatment groups in terms of survival (n=8 for agonist, n=8 for vehicle, 
P=.5590, log-rank test). 
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Figure 5: The weights of each mouse group over time. There was significant 
difference in weight over time, and the mice reacted to the treatment over time.  
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Figure 6: On the last day of treatment the weights between the vehicle and agonist 
showed no significant difference. However, there was significant difference between 
the agonist and wild type untreated and vehicle and wild type untreated mice 













Pikoulis (2016). "The TNBS-induced colitis animal model: An overview." Annals of 
Medicine and Surgery 11: 9-15.  
 
Bramhall, M., O. Flórez-Vargas, R. Stevens, A. Brass and S. Cruickshank (2015). 
"Quality of Methods Reporting in Animal Models of Colitis." Inflammatory Bowel 
Diseases 21(6): 1248-1259. 
 
Chassaing, B., J. D. Aitken, M. Malleshappa and M. Vijay-Kumar (2014). "Dextran 
Sulfate Sodium (DSS)-Induced Colitis in Mice." Current protocols in immunology / 
edited by John E. Coligan ... [et al.] 104: Unit-15.25. 
 
Foxx-Orenstein, A. E., J.-G. Jin and J. R. Grider (1998). "5-HT4 receptor agonists and 
δ-opioid receptor antagonists act synergistically to stimulate colonic propulsion." 
American Journal of Physiology-Gastrointestinal and Liver Physiology 275(5): G979-
G983. 
 
Hoffman, J. M., K. Tyler, S. J. Maceachern, O. B. Balemba, A. C. Johnson, E. M. 
Brooks, H. Zhao, G. M. Swain, P. L. Moses, J. J. Galligan, K. A. Sharkey, B. 
Greenwood–Van Meerveld and G. M. Mawe (2012). "Activation of Colonic Mucosal 
5-HT(4) Receptors Accelerates Propulsive Motility and Inhibits Visceral 
Hypersensitivity." Gastroenterology 142(4): 844-854.e844. 
 
Iyer, S. S. and G. Cheng (2012). "Role of Interleukin 10 Transcriptional Regulation in 
Inflammation and Autoimmune Disease." Critical reviews in immunology 32(1): 23-
63. 
 
Keubler, L. M., M. Buettner, C. Häger and A. Bleich (2015). "A Multihit Model: 
Colitis Lessons from the Interleukin-10–deficient Mouse." Inflammatory Bowel 
Diseases 21(8): 1967-1975. 
 
Kiesler, P., I. J. Fuss and W. Strober (2015). "Experimental Models of Inflammatory 
Bowel Diseases." Cellular and Molecular Gastroenterology and Hepatology 1(2): 
154-170. 
 
Kim, D. H. and J. H. Cheon (2017). "Pathogenesis of Inflammatory Bowel Disease 
and Recent Advances in Biologic Therapies." Immune Network 17(1): 25-40. 
 
M’Koma, A. E. (2013). "Inflammatory Bowel Disease: An Expanding Global Health 
Problem." Clinical Medicine Insights. Gastroenterology 6: 33-47. 
 
Neurath, M. F. (2012). "Animal Models of Inflammatory Bowel Diseases: 
Illuminating the Pathogenesis of Colitis, Ileitis and Cancer." Digestive Diseases 
30(suppl 1)(Suppl. 1): 91-94. 
 
Price, A. B. and B. C. Morson (1975). "Inflammatory bowel disease: the surgical 
pathology of Crohn's disease and ulcerative colitis." Hum Pathol 6(1): 7-29. 
67 
 
Rubio, C. A., C. Johansson and Y. Kock (1982). "A quantitative method of estimating 
inflammation in the rectal mucosa. III. Chronic ulcerative colitis." Scand J 
Gastroenterol 17(8): 1083-1087. 
 
Silva, F. A. R., B. L. Rodrigues, M. d. L. S. Ayrizono and R. F. Leal (2016). "The 
Immunological Basis of Inflammatory Bowel Disease." Gastroenterology Research 
and Practice 2016: 2097274. 
 
Spohn, S. N., F. Bianco, R. B. Scott, C. M. Keenan, A. A. Linton, C. H. O’Neill, E. 
Bonora, M. Dicay, B. Lavoie, R. L. Wilcox, W. K. MacNaughton, R. De Giorgio, K. 
A. Sharkey and G. M. Mawe (2016). "Protective Actions of Epithelial 5-

















CHAPTER 3: FINAL CONCLUSIONS AND FUTURE DIRECTIONS 
Summary and Conclusions: 
 Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the 
gastrointestinal tract that exists in three forms: Crohn’s Disease (CD), Ulcerative 
Colitis (UC), and Inflammatory Bowel Disease Unclassified (IBDU). IBD is 
characterized by its chronic inflammation, which can lead to obstruction and ulcers 
and is commonly accompanied by either severe diarrhea or constipation. Abdominal 
pain is also common, as is weight loss. Therapies for IBD include biologics, 
monoclonal antibodies, 5-aminosalicylates, and corticosteroids (Neurath, 2017). 
Steroids used like prednisone are not recommended for use long-term, and other 
therapies are either not very effective, or lose their efficacy over time. The goal of 
treatment, using drugs or by way of surgery, is to, according to the Mayo Clinic, 
reduce the inflammation that triggers the signs and symptoms. We continued the 
study of 5-HT4 receptor agonists, a novel therapeutic, which appears to serve an anti-
inflammatory and wound healing role. Results from the current study show that the 
activation of the 5-HT4 receptors in the colonic epithelium attenuated the 
development of inflammation in the IL-10 knockout animal model of colitis. In 
addition, the mice treated with agonist increases cell proliferation and enhances 
wound healing.  
Future Directions:  
 Potential future directions for this study include the addition of an antagonist 
plus agonist study. By using a 5-HT4 receptor antagonist combined with an agonist, 
we would be able to confirm the site of action of tegaserod. Tegaserod is known to 
have effect at other receptors, such as being an antagonist at the 5-HT2B receptor. If 
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an antagonist is given first, followed by the agonist treatment, the agonist should have 
no effect as its site of action is being blocked by the antagonist. This would then 
confirm the site of action of tegaserod. This is important because tegaserod has been 
reported to have off target effects leading to cardiovascular issues. While the evidence 
for this is weak, it would never the less be prudent to show that tegaserod mainly 
effects the 5-HT4 receptor.  
 It is also important to conduct further trials in which an alternate route of 
administration is used. Throughout the current study, the route of administration was 
by enema, directly into the lumen. This showed great efficacy in that we saw 
improved wound healing and anti-inflammatory effects. To expand on these results, it 
would be pertinent to study the effects of agonist activation of the 5-HT4 receptor by 
way of another route of administration, such as intraperitoneal administration. In the 
study conducted by Spohn and her colleagues, administration of tegaserod by 
intraperitoneal injection was less effective than administration by enema into the 
lumen (Spohn, Bianco et al. 2016). This would strengthen those results and show that 
enema is the most efficacious route of administering 5-HT4 receptor agonists in 
experimental animal models of colitis. It is important to note that oral administration 
would not be pertinent to study. It is known that there are potential adverse effects for 
oral administration of tegaserod that are a result of systemic absorption. The goal here 
is to determine therapeutic potential of tegaserod without systemic absorption i.e. 
administration of tegaserod intraluminally such that there is little-to-no systemic 
absorption.  
 It would also be important to increase the size of the study. The significance of 
the current study given the small sample size is promising, but to further elucidate the 
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results, more mice are needed. A larger “n” value would give a more accurate picture 
as to the wound healing and anti-inflammatory effects that are seen in the agonist 
treated mice. It would also clarify the weight loss and gain of the mice. Given a higher 
sample size, there would be further data as to which group, agonist or vehicle, 
maintains their weight, gains weight, or loses weight. Currently, there is no significant 
difference in the weights between either group. A possible explanation could be that 
the treatment is having a negative effect on the weight of the mice (they are losing 
weight as a result of treatment). The non-significance in weight could also be as a 
result of choosing mice for the agonist and vehicle groups at random and selecting 
smaller mice for the agonist treatment group. It would be prudent to continue 
treatment for this metric to ascertain a better picture as to what the treatment is doing 
to the weight of the mice.  
 Also, the use of a fecal lipocalin-2 ELISA would be prudent to run. The fecal 
lipocalin-2 ELISA is a measure of lipocalin-2 which is shown to be present in both 
the DSS and IL-10 knockout models of colitis (Chassaing, Srinivasan et al. 2012). 
The use of this readout would be to show a less severe colitis by way of lipocalin-2 
level. This would show the effect of the 5-HT4R treatment in an objective manner. In 
the current study, a fecal-lipocalin-2 ELISA was run to determine the severity of 
colitis (data not shown). In the current study, the n values found by examination of 
fecal material were too low to be considered statistically viable. Future studies 
conducted should utilize the fecal lipocalin-2 ELISA and increase the n value to be 
statistically viable. The presence of fecal lipocalin-2 i of colitis in both the DSS and 
IL-10 knockout models of colitis (Chassaing, Srinivasan et al. 2012). 
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 Lastly, it would be important to include longer studies for survival analysis. 
With the knowledge that the agonist treated mice have reduced inflammation and 
enhanced wound healing (Figures 1-3), it is likely that, given more time, the agonist 
would show a greater survival percent than the vehicle treated mice. The current study 
showed no difference in survival between groups, but the agonist group had later 
deaths (Figure 4) than the vehicle.  
 From the current study, further evidence has been reported for a novel 
treatment of colitis. The current study reports continuing evidence for the protective 
and anti-inflammatory actions of tegaserod reported in the work done by Spohn et al. 
Treatment of colitis in the IL-10 experimental model with the 5-HT4 receptor agonist 
tegaserod showed a decrease in inflammation in the animals treated, as well as wound 
healing effects. The effect of 5-HT4 receptors on the colonic epithelium is likely due 
to a variety of effects that include the promotion of mucus secretion from goblet cells, 
wound healing through increased proliferation, and anti-inflammation due to 
resolution of infiltration of inflammatory cells and less crypt abnormalities. This study 
provides further evidence that luminally restricted administration of 5-HT4 receptor 
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